bacterial strains and methods for single-cell protein or biomass production.

Abstract

To provide methods for producing protein using microorganisms.SOLUTION: The invention relates to a bacterial strain of the genus Xanthobacter and continuous culture processes for the production of protein or biomass using bacteria of the genus Xanthobacter, the process comprising supply of gases and minerals to the cells. The invention also relates to the products of these processes and use of these products in e.g., food or feed.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] This invention relates to the production of proteins and / or other polymers using microorganisms. In particular, this invention relates to novel bacterial strains and continuous culture methods for producing proteins or biomass using bacteria, in which gases and minerals are supplied to the cells. This invention also relates to products of these methods, such as food and feed, and the use of these products. [Background technology]

[0002] The increasing global population, climate change, and water scarcity are increasingly threatening traditional agriculture and the adequate supply of food and feed. Therefore, alternative sources of organic molecules such as proteins are being studied. A potential alternative is single-cell production, i.e., the production of proteins and / or other macromolecules using microorganisms.

[0003] Chemosynthetic autotrophic microorganisms capable of growing in minimal mineral media using hydrogen gas as an energy source and carbon dioxide as the sole carbon source have been demonstrated. For a review of these microorganisms, see, for example, "Shivelyetal (1998) Annu Rev Microbiol 52:191". Patent application WO2018144965 describes various microorganisms and bioprocesses for converting gaseous substrates into high-protein biomass. "Andersenetal (1979) Biochim Biophys Acta 585:1-11" describes mutant strains of Alcaligeneseutrophus, a hydrogen bacterium that readily grows under heterotrophic and autotrophic conditions. The characteristics of mutants with altered ribulose-1,5-bisphosphate carboxylase / oxygenase (RuBisCO) activity are described. "Ohmiya et al. (2003) J. Biosci. Bioeng. 95:549-561" demonstrates the application of microbial genes to the utilization of cumbersome biomass. "Yu Jianetal (2013) Int J Hydrogen Ener 38:8683-8690" describes carbon dioxide fixation by hydrogen-oxidizing bacterial isolates. A high energy efficiency of 50% was measured at a moderate oxygen concentration (10 mol%). [Prior art documents] [Patent Documents]

[0004] [Patent Document 1] International Publication No. WO2018 / 144965 [Non-patent literature]

[0005] [Non-Patent Document 1] Shivelyetal(1998)Annu Rev Microbiol 52:191 [Non-Patent Document 2] Andersenetal (1979) Biochim Biophys Acta 585:1-11 [Non-Patent Document 3] Ohmiya et al. (2003) J. Biosci. Bioeng. 95:549-561 [Non-Patent Document 4] Yu Jianetal (2013)Int J Hydrogen Ener 38:8683-8690 [Overview of the project]

[0006] However, various chemosynthetic autotrophic microorganisms differ in terms of growth rate, yield, biomass composition, and properties relevant to their use as food components, such as safety for human consumption, taste, smell, mouthfeel, and technical and functional properties in cooking. Not all chemosynthetic autotrophic microorganisms have sufficient growth rate and yield, and not all processes can be realistically upscaled to economically viable large-scale processes. To obtain sufficient production of functional proteins, for example in food and feed applications, it is important to find suitable products and processes that can be run on a large scale. This need is addressed by the present invention. [Means for solving the problem]

[0007] In a first main embodiment, the present invention relates to the isolated bacterial strain VTT-E-193585 or its derivatives.

[0008] In a further embodiment, the present invention relates to a culture composition comprising the bacterial strain of the present invention or a derivative thereof. Furthermore, the present invention relates to a method for the production of biomass and / or proteins, the method comprising culturing the bacterial strain of the present invention or a derivative thereof.

[0009] In a further embodiment, the present invention relates to a method for the production of biomass and / or protein, the method comprising culturing a bacterial strain of the genus Xanthobacter in a continuous culture using hydrogen as an energy source and an inorganic carbon source, the inorganic carbon source being carbon dioxide.

[0010] In a further main aspect, the invention relates to large amounts of proteins, biomass or non-protein cell or chemical components obtainable or obtained by the method of the invention, and to food or feed products obtainable or obtained by the method of the invention.

Brief Description of the Drawings

[0011] [Figure 1] Figure 1 shows the optical density measured at 600 nm (black circles) and the readings of the optical density probe in the 200 L culture of the chemolithoautotroph of the isolated bacterial strain deposited as VTT-E-193585. [Figure 2] Figure 2 shows the optical density measured at 600 nm during the parallel cultivation of 200 mL of the chemolithoautotroph of the isolated bacterial strain deposited as VTT-E-193585 in various nitrogen sources.

Embodiments for Carrying out the Invention

[0012] [Definitions] As used herein, the term "isolated", for example, in the context of a bacterial strain, means that it is separated from its natural environment. Preferably, the isolated bacterial strain is pure, i.e., does not contain other bacterial strains.

[0013] The term "derivative", as used herein in the context of a bacterial strain, refers to a bacterial strain derived from a reference strain, i.e., generated using the reference strain as a starting point. For example, a genetically engineered, or mutated, or genetically modified bacterial strain is an embodiment of such a derivative. Genetic modification includes point mutations, as well as insertions or deletions including the insertion or deletion of an entire locus or a fragment thereof. The derivative preferably has less than 10 genetic modifications, such as less than 5, such as 4, 3, 2, or 1, compared to the reference strain.

[0014] As used herein, the noun "culture" refers to a suspension of living cells in a liquid medium.

[0015] The term "biomass" has its usual meaning in the field of bacterial fermentation and refers to cellular material.

[0016] As used herein, the term “continuous culture” refers to a culture process in which fresh culture medium is continuously added to the culture and the medium containing the bacterial culture is continuously removed at essentially the same rate.

[0017] [Summary of the Invention and Examples] In a first main embodiment, the present invention relates to the isolated bacterial strain VTT-E-193585 or its derivatives.

[0018] The VTT-E-193585 strain was isolated from the Baltic Sea coast in Naantali, Finland. This organism can be grown under suitable bioreactor conditions, using a minimal mineral medium containing hydrogen as an energy source and carbon dioxide as a carbon source, even under limited oxygen conditions. 16S sequencing and Illumina metagenomics sequencing indicate that this strain most likely belongs to the genus Xanthobacter, but it is not a known species. Because dried cell powder has a high protein content and contains all essential amino acids, the bacterial strains are very suitable for food and feed applications. Furthermore, it contains more unsaturated fatty acids than saturated fatty acids and high levels of B vitamins. It also has low levels of peptidoglycans and lipopolysaccharides, which can cause allergies and toxicity. Toxicity analysis was conducted, and no genotoxicity or cytotoxicity was observed in the strain. Furthermore, this strain is generally susceptible to antibiotics.

[0019] Strain VTT-E-193585(SoF1) was deposited on June 11, 2019, into the VTT Culture Collection at the VTT Technical Research Centre of Finland Ltd (PO Box 1000, FI-02044 VTT, Finland), an international depositary under the Budapest Convention. Further information regarding the characteristics of the strains and methods for culturing them is provided in the examples of this specification.

[0020] In a preferred embodiment, if the strain is a derivative of strain VTT-E-193585, the derivative retains the ability to grow using hydrogen gas as an energy source and carbon dioxide as the sole carbon source.

[0021] In one embodiment, if the strain is a derivative of strain VTT-E-193585, the derivative includes the 16S ribosomal RNA described in SEQ ID NO: 1 or a 16S ribosomal RNA having nucleotide differences of up to 20 nucleotides from SEQ ID NO: 1, for example, differences of 1 to 10, for example, 1 to 5, for example, 1, 2, or 3 nucleotides from SEQ ID NO: 1.

[0022] [SEQ ID NO:1: 16S ribosomal RNA of strain VTT-E-193585]

[0023] In another embodiment, the present invention relates to a culture comprising the bacterial strain of the present invention or a derivative thereof. In a preferred embodiment, the volume of the culture is 100 mL or more, for example 1 L or more, for example 10 L or more, for example 1,000 L or more, for example 10,000 L or more, for example 50,000 L or more, for example 100,000 L or more, for example 200,000 L or more.

[0024] In a further embodiment, the present invention relates to a method for the production of biomass and / or proteins. The method comprises culturing a bacterial strain of the present invention or a derivative thereof. One embodiment is a method for biomass production. Another embodiment is a method for producing proteins. One embodiment of the method involves culturing a bacterial strain in a continuous culture using an inorganic carbon source containing hydrogen and carbon dioxide as energy sources. A further embodiment is a method for biomass production, which includes cultivating a bacterial strain in a continuous culture using an inorganic carbon source, including hydrogen and carbon dioxide, as energy sources. Various further embodiments of the method are described below in this specification.

[0025] In a further main embodiment, the present invention relates to a method for the production of biomass and / or proteins, the method comprising culturing a strain of Xanthobacter bacteria in a continuous culture using an inorganic carbon source including hydrogen and carbon dioxide as an energy source. One embodiment is a method for biomass production. In another embodiment, it is a method for producing proteins. Various further embodiments of the method are described below in this specification.

[0026] According to the genome sequence, the strain deposited with number VTT-E-193585 likely uses the Calvin-Benson-Basham cycle for carbon fixation, in which a carbon dioxide molecule binds to the five-carbon chain of ribulose 1,5-bisphosphate, forming two molecules of glyceric acid 3-phosphate. This allows the strain to synthesize all the other organic molecules necessary for growth. Energy from hydrogen is NAD + It most likely enters cells via hydrogenases and / or NiFeSe hydrogenases that reduce hydrogen. Essentially, it is when hydrogen (H2) is oxidized to H + NAD + This is a redox reaction in which ATP is reduced to NADH. In addition to ATP, NADH is one of the major energy carriers in living organisms. Alternatively, other energy equivalents are reduced by other hydrogenase enzymes that use H2. The Calvin-Benson-Basham cycle requires energy in the form of ATP and NADH / NADPH to fix CO2. This strain is most likely to produce ATP through oxidative phosphorylation, which consists of a four-protein complex that generates a membrane-wide proton concentration gradient. The proton concentration gradient is generated primarily using energy from NADH. This proton concentration gradient drives the ATP synthase complex to produce ATP. According to the genome sequence, this strain possesses bacterial F-type ATP synthase.

[0027] If the method is specified to involve culturing a bacterial strain using an inorganic carbon source, it should be understood that the inorganic carbon source is the primary carbon source of the culture. Therefore, although small amounts of organic carbon sources may be present in the culture, the main metabolism and growth of the culture is based on the utilization of inorganic carbon sources, preferably carbon dioxide, as the carbon source. Preferably, the proportion of carbon supplied to the culture, which is an organic substance, is less than 5% of the total carbon supplied to the culture during the method, for example, less than 1%, for example, less than 0.1%. Preferably, no organic carbon source is supplied to the method.

[0028] Similarly, if the method is specified to involve culturing a bacterial strain using hydrogen (H2) as an energy source, it should be understood that hydrogen is the primary energy source in the culturing. Therefore, while there may be other small amounts of energy sources present in the culture, such as ammonia which can be supplied as a nitrogen source, or small amounts of organic compounds, the primary metabolism and growth of the culture is based on the utilization of hydrogen as energy. In the overall method, hydrogen is preferably produced by water electrolysis, that is, by decomposing water into hydrogen gas and oxygen gas using electricity. Thus, the hydrogen gas and oxygen gas are supplied to the bioreactor from a nearby electrolytic cell. Alternatively, electrodes can be placed inside the bioreactor to produce hydrogen and oxygen within the bioreactor rather than in a separate electrolytic cell.

[0029] The inorganic carbon source containing carbon dioxide may include other inorganic carbon sources such as carbon monoxide. In one embodiment, only a gaseous carbon source is supplied to the culture. In a preferred embodiment, carbon dioxide is the sole, and indeed the only, inorganic carbon source supplied to the culture. In one embodiment, only gas and minerals are supplied to the culture, and the level of carbon dioxide in the supplied gas is between 10% and 50%, for example between 15% and 45%, for example between 20% and 40%, for example between 25% and 35%, for example between 26% and 30%.

[0030] In another embodiment, gas and minerals are supplied to the culture, and the level of hydrogen (H2) in the supplied gas is between 30% and 80%, for example between 35% and 75%, for example between 40% and 70%, for example between 45% and 65%, for example between 50% and 60%.

[0031] In another embodiment, gas and minerals are supplied to the culture, and the level of oxygen (O2) in the supplied gas is between 10% and 25%, for example between 15% and 20%, for example between 16% and 18%. In another embodiment, the level of oxygen supplied is such that the dissolved oxygen level in the culture is maintained between 5% and 10%.

[0032] In a preferred embodiment, only gas and minerals are supplied to the culture, and the supplied gas includes H2, CO2, and O2, with a percentage of H2 between 40% and 70%, a percentage of CO2 between 18% and 28%, and a percentage of O2 between 12% and 22%.

[0033] Typically, the method of the present invention includes the addition of a nitrogen source. The nitrogen source may be supplied in the form of an ammonium salt such as ammonium hydroxide, ammonium sulfate, or ammonium chloride, or a nitrate such as ammonia, urea, or potassium nitrate. In other embodiments, nitrogen gas (N2) is supplied as the nitrogen source. In preferred embodiments, the nitrogen source is an ammonium salt such as ammonium hydroxide or ammonium sulfate.

[0034] In one embodiment, the supplied nitrogen source is ammonium hydroxide at a concentration between 100 mg / L and 10 g / L, for example between 250 mg / L and 4 g / L, for example between 0.5 g / L and 2 g / L, for example between 0.75 g / L and 1.5 g / L.

[0035] Typically, the method of the present invention involves the addition of minerals such as ammonium, phosphates, potassium, sodium, vanadium, iron, sulfates, magnesium, calcium, molybdenum, manganese, boron, zinc, cobalt, selenium, iodine, copper, and / or nickel. Suitable mineral media are well-known technologies and are described, for example, in Table 4 on page 87 of "Thermophilic Bacteria CRC Press, Boca Raton, Florida, edited by Jacob K. Krist Jansson, 1992."

[0036] In one embodiment, the added minerals are one or more of the following: Ammonia, ammonium (e.g., ammonium chloride (NH4Cl), ammonium sulfate ((NH4)2SO4)), nitrates (e.g., potassium nitrate (KNO3)), urea, or organic nitrogen sources; phosphoric acid (e.g., disodium phosphate (Na2HPO4), potassium phosphate (KH2PO4), phosphoric acid (H3PO4), potassium dithiophosphate (K3PS2O2), potassium orthophosphate (K3PO4), disodium phosphate (Na2HPO4·2H2O), dipotassium phosphate (K2HPO4), or monopotassium phosphate) (KH2PO4)); sulfates; yeast extract; chelated iron (e.g., chelated with EDTA or citric acid); potassium (e.g., potassium phosphate (KH2PO4), potassium nitrate (KNO3), potassium iodide (KI), potassium bromide (KBr)); and other inorganic salts, minerals, and micronutrients (e.g., sodium chloride (NaCl), magnesium sulfate (MgSO4·7H2O) or magnesium chloride (MgCl2), calcium chloride (CaCl2), calcium sulfate (CaSO4) or calcium carbonate). (CaCO3), manganese sulfate (MnSO4·7H2O) or manganese chloride (MnCl2), ferric chloride (FeCl2), ferrous sulfate (FeSO47H2O) or ferrous chloride (FeCl24H2O), sodium bicarbonate (NaHCO3) or sodium carbonate (Na2CO3), zinc sulfate (ZnSO4) or zinc chloride (ZnCl2), ammonium molybdate (NH4MoO4) or sodium molybdate (Na2MoO4·2H2O), copper sulfate (CuSO4) or copper chloride (CuCl2·2H2O), cobalt chloride (CoCl2·6H2O) or cobalt sulfate (CoSO4), aluminum chloride (AlCl3·6H2O), lithium chloride (LiCl), boric acid (H3BO3), nickel chloride (NiCl2·6H2O) or nickel sulfate (NiSO4), tin chloride (SnCl2·H2O), barium chloride (BaCl2·2H2O), copper selenite (CuSeO45H2O), sodium selenite (Na2SeO4) or sodium selenite (Na2SeO3), sodium metavanadate (NaVO3), chromium salts).

[0037] In preferred embodiments, the method of the present invention includes the addition of one, more, or all of the following: NH4OH, KH2PO4, Na2HPO4·2H2O, NaVO3·H2O, FeSO4x7H2O, MgSO4·7H2O, CaSO4, Na2MoO4·2H2O, MnSO4·7H2O, ZnSO4·7H2O, H3BO3, CoSO4, CuSO4, and NiSO4.

[0038] In one embodiment, the culture medium supplied to the cells contains less than 1 g / L of chloride salt, for example, less than 0.25 g / L, for example less than 0.1 g / L, for example less than 0.025 g / L, for example less than 0.01 g / L. In one embodiment, no chloride salt is supplied to the culture.

[0039] In another embodiment, no vitamins are supplied during the method; that is, the culture medium provided to the culture does not contain vitamins.

[0040] In another embodiment, no amino acids are supplied during the method; that is, the culture medium provided to the culture does not contain amino acids.

[0041] In another embodiment, no organic compounds are supplied during the method; that is, the culture medium provided to the culture does not contain organic compounds.

[0042] In certain embodiments, the pH of the bacterial culture is controlled to a specific level. In certain embodiments, the pH is controlled to be within an optimal range for the maintenance and / or growth of bacteria and / or the production of organic compounds. In one embodiment, the pH in the culture is maintained between 5.5 and 8.0, for example, between 6.5 and 7.0, such as 6.8.

[0043] In certain embodiments, the temperature of the bacterial culture is controlled. In certain embodiments, the temperature is controlled to be within an optimal range for the maintenance and / or growth of the bacteria and / or the production of organic compounds. In one embodiment, the culture is grown at a temperature between 28°C and 32°C, for example, between 25°C and 40°C, and between 30°C.

[0044] Typically, the method of the present invention is carried out in a bioreactor. The bioreactor is used for culturing cells that can be maintained at a specific stage of the cell growth curve. The use of bioreactors offers many advantages for cultivating chemosynthetic autotrophic organisms. In general, control of growth conditions, including dissolved carbon dioxide, oxygen, and other gases such as hydrogen, as well as other dissolved nutrients, trace elements, temperature, and pH, becomes easier within a bioreactor. Nutrient media and gases may be added to the bioreactor as batch additions, periodically, in response to detected depletion or programmed set values, or continuously while the culture is growing and / or being maintained. In continuous culture methods, nutrient media and gases are added to the bioreactor continuously. Furthermore, the bacteria-containing culture medium is continuously removed from the bioreactor.

[0045] In a preferred embodiment, the volume of the bacterial culture is 100 mL or more, for example 1 L or more, 10 L or more, for example 100 L or more, for example 1,000 L or more, for example 10,000 L or more, for example 50,000 L or more, for example 100,000 L or more, for example 200,000 L or more.

[0046] In one embodiment, the productivity of the culture is a cell dry weight per liter per hour that is greater than 0.9g, such as a cell dry weight of more than 0.1g, for example more than 0.2g, for example more than 0.3g, for example more than 0.4g, for example more than 0.5g, for example more than 0.6g, for example more than 0.7g, for example more than 0.8g, for example more than 1g.

[0047] Bacteria can be inoculated directly from a cell bank or via small-scale seed culture. Preferably, the supply of fresh culture medium to the culture and the removal of used medium containing bacteria are performed at the same rate so as to maintain the same volume in the bioreactor.

[0048] In one embodiment, after an initial stage in which a suitable cell density is reached, the bacteria proliferate in a steady or pseudo-steady state, with an OD greater than 5, for example between 50 and 200, for example between 50 and 100, for example greater than 10, for example greater than 20 600 In this case, it remains continuously in the logarithmic period.

[0049] In one embodiment of the method of the present invention, the bacterial strain is 0.04-0.12h -1 It has a growth rate of [value missing].

[0050] In another embodiment of the method of the present invention, the liquid supply rate in the continuous phase is 50-80% of the growth rate.

[0051] Xanthobacter is a genus of Gram-negative bacteria belonging to the family Xanthobacteraceae.

[0052] In one embodiment, the xanthobacter strain used in the method of the present invention is a strain that uses the Calvin-Benson-Basham cycle to convert carbon dioxide into organic compounds, such as glucose, which is essential for living organisms.

[0053] In one embodiment, the xanthobacter strain used in the method of the present invention is a strain that uses NiFeSe hydrogenase to convert hydrogen (H2) into a cellular energy equivalent.

[0054] In one embodiment, the xanthobacter strain used in the method of the present invention converts hydrogen (H2) into cellular energy equivalents using NAD. + - This strain utilizes reducing hydrogenase.

[0055] One embodiment is a xanthobacter strain used in the present invention's method capable of nitrogen fixation.

[0056] In one embodiment, the bacterial strain used in the method of the present invention is selected from the group consisting of X. agilis, X. aminoxidans, X. autotrophicus, X. flavus, X. tagetidis, X. viscosus, Xanthobacter sp. 126, Xanthobacter sp. 91, and VTT-E-193585 strain.

[0057] In preferred embodiments, the bacterial strain used in the method of the present invention is VTT-E-193585 or X. tagetidis. Most preferably, the strain used in the method of the present invention is VTT-E-193585.

[0058] In another embodiment, the bacterial strain used in the method of the present invention is the 16S ribosomal RNA shown in SEQ ID NO: 1, or 16S ribosomal RNA having a difference of up to 20 nucleotides from SEQ ID NO: 1, for example, a difference of 1 to 10 from SEQ ID NO: 1, for example, a difference of 1 to 5, for example, a difference of 1, 2 or 3 nucleotides.

[0059] In another embodiment, the bacterial strain used in the method of the present invention has a gene encoding a ribulose-1,5-bisphosphate carboxylase / oxygenase (RuBisCO) large chain having the sequence shown in SEQ ID NO: 3, or a sequence having more than 93% identity to the sequence shown in SEQ ID NO: 3, for example more than 95%, for example more than 96%, for example more than 97%, for example more than 98%, for example more than 99%.

[0060] In another embodiment, the bacterial strain used in the method of the present invention has a gene encoding a ribulose-1,5-bisphosphate carboxylase / oxygenase (RuBisCO) small chain having the sequence shown in SEQ ID NO: 5, or a sequence having more than 83% identity to the sequence shown in SEQ ID NO: 5, for example more than 86%, for example more than 90%, for example more than 95%, for example more than 96%, for example more than 98%, for example more than 97%, for example more than 99%.

[0061] [SEQ ID NO:2: Nucleotide sequence of ribulose diphosphate carboxylase large chain]

[0062] [SEQ ID NO:3: Amino acid sequence of ribulose diphosphate carboxylase large chain] MGAEATVGQITDAKKRYAAGVLKYAQMGYWNGDYVPKDTDLLAVFRITPQAGVDPVEAAAAVAGESSTATWTVVWTDRLTAADVYRAKAYKVEPVPGQEGQYFCYIAYDLDLFEEGSIANLT ASIIGNVFSFKPLKAARLEDMRLPVAYVKTFRGPPTGIVVERERLDKFGRPLLGATTKPKLGLSGKNYGRVVYEALKGGLDFVKDDENINSQPFMHWRDRFLYCMEAVNKAQAETGEVKGHY LNITAGTMEEMYRRAEFAKELGSVVVMVDLIIGWTAIQSMSNWCRENDMILHMHRAGHGTYTRQKSHGVSFRVIAKWLRLAGVDHLHTGTAVGKLEGDPMTVQGFYNVCRETTTQQDLTRGL FFEQDWGGIRKVMPVASGGIHAGQMHQLIDLFGEDVVLQFGGGTIGHPDGIQAGATANRVALETMILARNEGRDIRNEGPEILVEAAKWCRPLRAALDTWGEVTFNYASTDTSDYVPTASVA

[0063] [SEQ ID NO:4: Nucleotide sequence of the ribulose diphosphate carboxylase small chain] ATGCGCATCACCCAAGGCTCCTTCTCCTTCCTGCCGGACCTCACCGACACGCAGATCAAGGCCCAGGTGCAATATTGCCTGGACCAGGGCTGGGCGGTCTCGGTGGAGCACACCGACGATCCCCACCCGCGCAACACCTATTGGGAGATGTGGGGCCCGCCCATGTTCGATCTGCGCGACGCGGCCGGCGTCTTCGGCGAGA TCGAAGCCTGCCGGGCCGCCAATCCCGAGCATTATGTGCGGGTGAACGCCTTCGATTCCAGCCGCGGATGGGAGACGATCCGCCTGTCCTTCATCGTCAGCGGCCCACCGTGGAAGAGGGCTTCCGCCTCGACCGCACCGAAGGCAAGGGCCGCAACCAGAGCTACGCCATGCGCTACCGGGCGCAGTTTCGCGCCGCGCTGA

[0064] [SEQ ID NO:5: Amino acid sequence of ribulose diphosphate carboxylase small chain] Amino acid sequence of Ribulose bisphosphate carboxylase small chain: MRITQGSFSFLPDLTDTQIKAQVQYCLDQGWAVSVEHTDDPHPRNTYWEMWGPPMFDLRDAAGVFGEIEACRAANPEHYVRVNAFDSSRGWETIRLSFIVQRPTVEEGFRLDRTEGKGRNQSYAMRYRAQFAPR

[0065] In another embodiment, the bacterial strain used in the method of the present invention has NAD having the sequence shown in Sequence ID No. 7. + The gene sequence encoding the reducing hydrogenase HoxS subunit alpha, or the sequence shown in Sequence ID No. 7, includes sequences having more than 70% identity, such as more than 80%, more than 90%, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0066] In another embodiment, the bacterial strain used in the method of the present invention is NAD having the sequence shown in SEQ ID NO: 9 + a sequence encoding the NAD-reducing hydrogenase HoxS subunit beta, or a sequence having an identity of more than 77%, for example more than 80%, for example more than 90%, for example more than 95%, for example more than 96%, for example more than 97%, for example more than 98%, for example more than 99% identity to the sequence shown in SEQ ID NO: 9.

[0067] In another embodiment, the bacterial strain used in the method of the present invention is NAD having the sequence shown in SEQ ID NO: 11 + a gene encoding the NAD-reducing hydrogenase HoxS subunit gamma, or a sequence having an identity of more than 70%, for example more than 80%, for example more than 90%, for example more than 95%, more than 96%, for example more than 97%, for example more than 98%, more than 99% identity to the sequence shown in SEQ ID NO: 11.

[0068] In another embodiment, the bacterial strain used in the method of the present invention is NAD having the sequence shown in SEQ ID NO: 13 + - a gene encoding the NAD-reducing hydrogenase HoxS subunit delta, or a sequence having an identity of more than 79%, for example more than 80%, for example more than 90%, for example more than 95%, for example more than 96%, for example more than 97%, for example more than 98%, for example more than 99% identity to the sequence shown in SEQ ID NO: 13.

[0069] [SEQ ID NO: 6 (SEQ ID NO: 6): NAD + - nucleotide sequence of the NAD-reducing hydrogenase HoxS subunit alpha]

[0070] [SEQ ID NO:7):NAD + [Amino acid sequence of the reducing hydrogenase HoxS subunit alpha] MMPSEPHGAGMPPPREAAAAVPTPQEVSAVVAEVVADAVASVGGARTRLMDIVQLAQQRLGHLSEETMAAIAARLAIPPVEVADMVSFYAFLNRAPKGRYHIRLSRSPISLMKGAEAVAAAFCQILGIAMGETSQDGDFTLEWTNDIGMADQEPAALV NGTVMTQLAPGDAAIIVGRLRAHHAPNALPLFPGAGVAGSGLPHARIRPSLVMPGQLLFREDHTTPGAGIKAALALTPDEVVQKVSAARLRGGAGFPTGLKWKLCRQSPATTRHVICNADEGEPGTFKDRVLLTQAPHLMFDGMTIAGYALGAREG VVYLRGEYAYLWEPLHAVLRERYGLGLAGANILGHAGFDFDIRIQLGAGAYICGEESALVESLEGKRGSPRDRPPFPTVRGHLQQPTAVDNVETFACAARILEDGVEAFAGIGTPESAGTKLLSVSGDCPRPGVYEVPFGLTVNALLDLVGAPDAAFV QMGGPSGQCVAPKDYGRRIAFEDLPTGGSMVMVFGPGRDVLAMVREFADFFAGESCGWCTPCRVGTTLLKEELDKLLANRATLADIRALETLATTVSRTSRCGLGQTAPNPILSTMRNLPEAYEARLRPEDFLPWASLDEALKPAIVIQGRAPVPEEEA

[0071] [SEQ ID NO:8:NAD] + [Nucleotide sequence of the HoxS subunit beta of the reducing hydrogenase]

[0072] [SEQ ID NO:9):NAD + [Amino acid sequence of the reducing hydrogenase HoxS subunit beta] MSRGSPDAGKDRTMSATDGTAPRKIVIDPVTRVEGHGKVTIRLDEAGAVEDARFHIVEFRGFERFIQGRMYWEVPLIIQRLCGICPVSHHLAAAKAMDQVAGVDRVPPTAEKLRRLMHYGQVL QSNALHIFHLASPDLLFGFDAPAEQRNIIAVLQRYPEIGKWAIFIRKFGQEVIKATGGRKIHPTSAIPGGVNQNLAVEDRDALRAKVGEIISWCMAALDHHKAYVAENRALHDSFAAFPSAFMS LVGPDGGMDLYDGTLRVIDAEGAPLIEGAPPASYRDHLIEEVRPWSYLKFPHLRAFGRDGWYRVGPLAQVNCAASIDTPRAEAARRDFMAEGGGKPVHATLAYHWARLIVLVHCAEKIEQLLF DDDLQGCDLRAEGTRRGEGVAWIEAPRGTLIHHYEVDENDQVRRANLIVSTTHNNEAMNRAVRQVAKTDLSGREITEGLLNHIEVAIRAFDPCLSCATHALGQMPLIVTLEDASGAEIARGVKE

[0073] [SEQ ID NO:10): NAD + [Nucleic acid sequence of the reducing hydrogenase HoxS subunit gamma] ATGAGCGAGACCCCCTTCACCTTTACCGTGGACGGCATCGCGGTCCCGGCCACCCCCGGCCAGAGCGTCATCGAGGCGTGCGATGCGGCGGGCATCTATATCCCGCGCCTGTGCCACCACCCGGACCTGCCGCCGGCGGGCCATTGCCGGGTGTGCACCTGCATCATCGACGGGCGGCCGGCCAGCGCCTGCACCATGCCCGCCGCCAGGGGCATGGTGGTGGAGAACGAGACGCCCGCTTTGCTGGCGGAGCGGCGCACGCTGATCGAGATGCTGTTCGCGGAAGGCAACCATTTCTGCCAGTTCTGCGAGGCGAGCGGCGATTGCGAATTGCAGGCGCTGGGCTACCTGTTCGGCATGGTGGCCCCGCCCTTCCCCCATCTGTGGCCGAAGCGGCCGGTGGATGCCAGCCATCCGGATATCTATATCGACCACAATCGCTGCATCCTGTGCTCGCGCTGCGTGCGCGCCTCGCGCACCCTGGACGGCAAGTCCGTGTTCGGCTTCGAGGGGCGCGGCATCGAGATGCATCTGGCGGTGACCGGCGGGCACCTGGACGACAGCGCCATCGCCGCCGCCGACAGGGCGGTTGAGATGTGCCCGGTGGGCTGCATCGTCCTCAAGCGCACCGGCTACCGCACGCCCTATGGCCGGCGGCGCTACGACGCCGCGCCCATCGGCTCCGACATCACCGCCCGGCGCGGCGGCGCGAAGGACTGA

[0074] [SEQ ID NO:11: NAD + [Amino acid sequence of the reducing hydrogenase HoxS subunit gamma] MSETPFTFTVDGIAVPATPGQSVIEACDAAGIYIPRLCHHPDLPPAGHCRVCTCIIDGRPASACTMPAARGMVVENETPALLAERRTLIEMLFAEGNHFCQFCEASGDCELQALGYLFGMVAPPFPHLWPKRPVDASHPDIYIDHNRCILCSRCVRASRTLDGKSVFGFEGRGIEMHLAVTGGHLDDSAIAAADRAVEMCPVGCIVLKRTGYRTPYGRRRYDAAPIGSDITARRGGAKD

[0075] [Accession No. 12 (SEQ ID NO:12): NAD + -reduced hydrogenase HoxS subunit delta nucleotide sequence] ATGGCCAAGCCCAAACTCGCCACCTGCGCGCTGGCCGGCTGCTTCGGCTGCCACATGTCCTTCCTGGACATGGACGAGCGCATCGTCGAGCTCATCGACCTGGTGGACCTCGACGTCTCGCCCCTCGACGACAAGAAAAACTTCACCGGCATGGTGGAAATCGGCCTGGTGGAAGGCGGCTGCGCCGACGAGCGCCATGTGAAGGTGCTGCGCGAGTTCCGCGAGAAATCCCGCATCCTGGTGGCGGTGGGCGCCTGCGCCATCACCGGCGGCATCCCGGCATTGCGCAACCTCGCCGGCCTCGACGAATGCCTGAGGGAAGCCTACCTCACCGGCCCCACGGTGGAAGGCGGCGGGCTCATTCCCAACGACCCGGAGCTGCCGCTGCTGCTGGACAAGGTCTATCCGGTGCAGGACTTCGTGAAGATCGACCATTTCCTGCCCGGCTGCCCGCCCTCGGCCGACGCCATCTGGGCGGCTCTGAAGGCGCTGCTGACCGGCACCGAGCCGCATCTGCCCTACCCGCTTTTCAAGTACGAATGA

[0076] [Accession No. 13 (SEQ ID NO:13): NAD +- Amino acid sequence of the reduced hydrogenase HoxS subunit delta] MAKPKLATCALAGCFGCHMSFLDMDERIVELIDLVDLDVSPLDDKKNFTGMVEIGLVEGGCADERHVKVLREFREKSRILVAVGACAITGGIPALRNLAGLDECLREAYLTGPTVEGGGLIPNDPELPLLLDKVYPVQDFVKIDHFLPGCPPSADAIWAALKALLTGTEPHLPYPLFKYE

[0077] In another embodiment, the bacterial strain used in the method of the present invention comprises a gene encoding a NiFeSe hydrogenase large subunit having the sequence shown in SEQ ID NO: 15, or a sequence having more than 84% identity to the sequence shown in SEQ ID NO: 15, such as more than 90% identity, more than 95% identity, more than 96% identity, more than 97% identity, more than 98% identity, or more than 99% identity.

[0078] In another embodiment, the bacterial strain used in the method of the present invention comprises a gene encoding a NiFeSe hydrogenase small subunit having the sequence shown in SEQ ID NO: 17, or a sequence having more than 90% identity to the sequence shown in SEQ ID NO: 17, for example, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0079] [SEQ ID NO:14: Nucleotide sequence of the periplasmic NiFeSe hydrogenase large subunit]

[0080] [SEQ ID NO:15: Amino acid sequence of the periplasmic NiFeSe hydrogenase large subunit] MSAETRRLVVGPFNRVEGDLEVRLDVQDGRVQQAFVSSPLFRGFERILEGRDPRDALVIAPRICGICSVSQSHAAALALAGLQGIAPTHDGRIATNLIVAAENVADHLTHFHVFFMPDFAR AVYEDRPWFAQAARRFKANQGVSVRRALQTRATLLHVLGTLAGRWPHTLALQPGGVTRSADQHDRMRLLATLKAVRAALEETLFGAPLEEVAALDGAAAVEAWRANGPEGDFRLFLEIAAD LELDRLGRAHDRFLSFGAYAQDEGRLYGAGTFEAGTAGGLDPNAITEDHAFARMEDRAAPHAPFDGSTFPDADDTEGYTWCKAPRLAGLPFETGAFARQVVAGHPLARDLVTREGGTVRSR VVGRLLETARTLIAMEGWVKELRPEGPWCAQGHLPQEGRAFGLTEAARGALGHWMVVEKGRIARYQIIAPTTWNFSPRDGAGLPGPLETALVGAPVRQGETTPVSVQHIVRSFDPCMVCTVH

[0081] [SEQ ID NO:16: Nucleotide sequence of the periplasmic NiFeSe hydrogenase small subunit] ACGGGGGAGGAAGCCCGCGCCATCTTCGACGCCATCCTTGCCGGCGTTATCGTCCTCGACGCCCTGTGCGTGGAAGGCGCGCTGCTGCGCGGGCCGAACGGCACCGGGCGCTTCCATGTGCTGGCGGGCACGGACACCCCCACCATCGACTGGGCGCGGCAGCTCGCCGGCATGGCGCGCCACGTGGTGGCGGTGGGCACCTGCGCCGCCTATGGGGGCGTGACGGCGGCGGGCATCAACCCCACCGATGCCTGCGGCCTCCAGTTCGACGGACGCCGGAAGGGTGGGGCGCTGGGGGCGGACTTCCGCTCCCGCTCGGGGCTTCCGGTCATCAATGTGGCCGGCTGCCCCACCCATCCCAACTGGGTGACGGAAACCCTGATGCTGCTCGCCTGCGGCCTGCTGGGCGAGGCCGACCTCGACGTCTATGGCCGCCCGCGCTTCTATGCGGACCTGCTGGTGCATCACGGCTGCCCGCGCAACGAATACTATGAATACAAGGCGAGCGCCGAGAAGATGAGCGACCTCGGCTGCATGATGGAGCATCTGGGCTGCCTCGGCACCCAGGCCCACGCCGACTGCAACACGCGCCTTTGGAATGGCGAGGGCTCGTGCACCCGCGGCGGCTATGCCTGCATCAACTGCACGGCGCCGGAATTCGAGGAGCCGGGCCACGCCTTCCTGGAGACGCCCAAGATCGGCGGCATCCCCATCGGCCTGCCCACCGACATGCCCAAGGCCTGGTTCATCGCCTTGTCCTCCCTCGCCAAGGCGGCGACGCCGGAGCGGCTGCGCAAGAACGCGGTGTCCGACCATGTGGTCACGCCGCCCGCCGTCAAGGACATCAAGCGGCGATGA

[0082] [SEQ ID NO:17: Amino acid sequence of the small subunit of periplasmic NiFeSe hydrogenase] MSTPFSVLWLQSGGCGGCTMSLLCAEAPDLATTLDAAGIGFLWHPALSEETGEEARAIFDAILAGVIVLDALCVEGALLRGPNGTGRFHVLAGTDTPTIDWARQLAGMARHVVAVGTCAAYGGVTAAGINPTDACGLQFDGRRKGGALGADFRSRSGLPVINVAGCP THPNWVTETLMLLACGLLGEADLDVYGRPRFYADLLVHHGCPRNEYYEYKASAEKMSDLGCMMEHLGCLGTQAHADCNTRLWNGEGSCTRGGYACINCTAPEFEEPGHAFLETPKIGGIPIGLPTDMPKAWFIALSSLAKAATPERLRKNAVSDHVVTPPAVKDIKRR

[0083] In another embodiment, the bacterial strain used in the method of the present invention includes a gene encoding the ATP synthase gamma chain atpG_1, which includes the sequence shown in SEQ ID NO: 19, or a sequence having more than 70% identity to the sequence shown in SEQ ID NO: 19, such as more than 80%, more than 90%, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0084] In another embodiment, the bacterial strain used in the method of the present invention includes a sequence encoding ATP synthase subunit alpha atpA_1 having the sequence shown in SEQ ID NO: 21, or a sequence having more than 78% identity to the sequence shown in SEQ ID NO: 21, such as more than 80%, more than 90%, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0085] In another embodiment, the bacterial strain used in the method of the present invention includes a gene encoding the ATP synthase subunit b atpF_1 having the sequence shown in SEQ ID NO: 23, or a sequence having more than 62% identity to the sequence shown in SEQ ID NO: 23, such as more than 70% identity, more than 80% identity, more than 90% identity, more than 95% identity, more than 96% identity, more than 97% identity, more than 98% identity, or more than 99% identity.

[0086] In another embodiment, the bacterial strain used in the method of the present invention includes an ATP synthase subunit c having the sequence shown in SEQ ID NO: 25, a gene encoding sodium ion specificity atpE_1, or a sequence having more than 90% identity to the sequence shown in SEQ ID NO: 25, for example, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0087] In another embodiment, the bacterial strain used in the method of the present invention includes a gene sequence encoding the ATP synthase subunit a atpB_1 having the sequence shown in SEQ ID NO: 27, or a sequence having more than 80% identity to the sequence shown in SEQ ID NO: 27, such as more than 90%, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0088] In another embodiment, the bacterial strain used in the method of the present invention includes a gene encoding the ATP synthase epsilon chain atpC_1 having the sequence shown in SEQ ID NO: 29, or a sequence having more than 71% identity to the sequence shown in SEQ ID NO: 29, such as more than 80%, more than 90%, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0089] In another embodiment, the bacterial strain used in the method of the present invention comprises a gene encoding ATP synthase subunit beta atpD_1 having the sequence shown in SEQ ID NO: 31, or a sequence having more than 84% identity to the sequence shown in SEQ ID NO: 31, such as more than 90% identity, more than 95% identity, more than 96% identity, more than 97% identity, more than 98% identity, or more than 99% identity.

[0090] In another embodiment, the bacterial strain used in the method of the present invention includes a gene encoding ATP synthase subunit beta atpD_2, which includes the sequence shown in SEQ ID NO: 33, or a sequence having more than 97% identity to the sequence shown in SEQ ID NO: 33, for example, more than 98% identity, for example more than 99% identity.

[0091] In another embodiment, the bacterial strain used in the method of the present invention includes a gene encoding the ATP synthase gamma chain atpG_2 having the sequence shown in SEQ ID NO: 35, or a sequence having more than 86% identity to the sequence shown in SEQ ID NO: 35, such as more than 90% identity, more than 95% identity, more than 96% identity, more than 97% identity, more than 98% identity, or more than 99% identity.

[0092] In another embodiment, the bacterial strain used in the method of the present invention includes a gene encoding ATP synthase subunit alpha atpA_2 having the sequence shown in SEQ ID NO: 37, or a sequence having more than 98% identity to the sequence shown in SEQ ID NO: 37, for example, more than 99% identity.

[0093] In another embodiment, the bacterial strain used in the method of the present invention includes a gene encoding the sequence shown in SEQ ID NO: 39, or a gene having more than 85% identity to the sequence shown in SEQ ID NO: 39, such as more than 90% identity, more than 95% identity, more than 96% identity, more than 97% identity, more than 98% identity, or more than 99% identity.

[0094] In another embodiment, the bacterial strain used in the method of the present invention comprises a gene encoding the ATP synthase subunit b atpF_2 having the sequence shown in SEQ ID NO: 41, or a sequence having more than 87% identity to the sequence shown in SEQ ID NO: 41, such as more than 90% identity, more than 95% identity, more than 96% identity, more than 97% identity, more than 98% identity, or more than 99% identity.

[0095] In another embodiment, the bacterial strain used in the method of the present invention comprises a gene encoding the ATP synthase subunit b'atpG_3 having the sequence shown in SEQ ID NO: 43, or a sequence having more than 81% identity to the sequence shown in SEQ ID NO: 43, such as more than 90% identity, more than 95% identity, more than 96% identity, more than 97% identity, more than 98% identity, or more than 99% identity.

[0096] In another embodiment, the bacterial strain used in the method of the present invention includes a gene encoding the ATP synthase subunit c atpE_2 having the sequence shown in SEQ ID NO: 45, or a sequence having more than 98% identity to the sequence shown in SEQ ID NO: 45, for example, more than 99% identity.

[0097] In another embodiment, the bacterial strain used in the method of the present invention includes a gene encoding the ATP synthase subunit a atpB_2 having the sequence shown in SEQ ID NO: 47, or a sequence having more than 92% identity to the sequence of SEQ ID NO: 47, for example, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0098] In another embodiment, the bacterial strain used in the method of the present invention includes a gene encoding ATP synthase protein I atpI having the sequence shown in SEQ ID NO: 49, or a sequence having more than 60% identity to the sequence of SEQ ID NO: 49, for example, more than 70%, more than 80%, more than 90%, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0099] [SEQ ID NO: 18: Nucleotide sequence of ATP synthase gamma chain atpG_1] GTGACCGAGCGCCTGTCCGACGTCAACGCCCGCATCGCCTCGGTGCGGCAGCTCTCATCGGTCATCACGGCCATGCGGGGCATTGCGGCGGCGCGGGCGCGGGAGGCGCGGGGTCGGCTCGACGGCATCCGCGCCTATGCGCAGACCATCGCCGAGGCCATCGGCCATGTGCTCGCCGTGCTGCCCGAGGAGGCCCGCGCCCGGTCCTCCGGGCACCGGCATCGGGGCCATGCGGTCATCGCCCTGTGCGCGGAGCAGGGCTTTGCCGGCGTCTTCAACGAGCGGGTGCTGGACGAGGCCGCCCGGCTGCTGACCGGCGGGGCGGGGCCGGCCGAGCTGCTGCTGGTGGGCGACCGGGGCCTGATGGTGGCCCGCGAGCGGGGGCTCGATGTCTCCTGGTCGGTGCCCATGGTGGCCCATGCGGGCCAGGCCTCGGCGCTGGCGGACCGCATCAGCGAGGAGCTCTACCGGCGGATCGATGCGGGACGGGTGACGCGGGTGTCGGTGGTGCACGCCGAGCCCGCCGCGTCCGCCGCCATCGAGACGGTGGTGAAAGTGCTGGTGCCGTTCGACTTCGCCCGCTTCCCCCTGGCGCGGGTGGCATCCGCCCCGCTCATGACCATGCCGCCGCCGCGGCTGCTGGCCCAGCTGTCGGAGGAATATGTGTTCGCCGAGCTGTGCGAGGCGCTCACCTTGTCCTTCGCGGCGGAGAACGAGGCCCGCATGCGGGCCATGATCGCCGCCCGCGCCAATGTGGCCGATACCCTGGAGGGCCTCGTCGGCCGCGCCCGGCAGATGCGCCAGGAGGAGATCACCAACGAGATCATCGAGCTGGAAGGCGGCGCCGGCAGCGCCCGGCATGCGGATTGA

[0100] [SEQ ID NO:19: Amino acid sequence of ATP synthase gamma chain atpG_1] MTERLSDVNARIASVRQLSSVITAMRGIAAARAREARGRLDGIRAYAQTIAEAIGHVLAVLPEEARARSSGHRHRGHAVIALCAEQGFAGVFNERVLDEAARLLTGGAGPAELLLVGDRGLMVARERGLDVSWSVPMVAHAGQA SALADRISEELYRRIDAGRVTRVSVVHAEPAASAAIETVVKVLVPFDFARFPLARVASAPLMTMPPPRLLAQLSEEYVFAELCEALTLSFAAENEARMRAMIAARANVADTLEGLVGRARQMRQEEITNEIIELEGGAGSARHAD

[0101] [SEQ ID NO:20: Nucleotide sequence of ATP synthase subunit alpha atpA_1]

[0102] [SEQ ID NO:21: Amino acid sequence of ATP synthase subunit alpha atpA_1] MSTGAQASEDWLTRSRAALAGTRLSQQSQSVGRVEEMADGIARVSGLPDVRLDELLTFEGGQTGYALTLDRTEIAVVLLDDASGVEAGARVFGTGEVVKVPVGPGLLGRIVDPLGRPMDRSEPVVAQ AHHPIERPAPAIIARDLVSQPVQTGTLVVDALFSLGRGQRELIIGDRATGKTAIAVDTIISQKHSDIVCIYVAVGQRAAAVERVVEAVRAHGAIERCIFVVASAAASPGLQWIAPFAGMTMAEYFRDN GQHALIIIDDLTKHAATHRELALLTHEPPGREAYPGDIFYVHARLLERAAKLSAELGGGSLTALPIAETDAGNLSAYIPTNLISITDGQIVLDSRLFAANQRPAVDVGLSVSRVGGKAQHPALRAVSG RIRLDYSQFLELEMFTRFGGITDTRVKAQITRGERIRALLTQPRFSTLRLQDEVALLAALAEGVFDTLAPGLMGAVRARIPAQLDAQVKDVASALAEGKVLEEGLHARLVAAVRAVAADVAATAKAGP

[0103] [SEQ ID NO:22: Nucleotide sequence of ATP synthase subunit b atpF_1] ATGCAGATCGACTGGTGGACGCTGGGCCTGCAGACGGTCAACGTCCTCGTTCTCATCTGGCTCCTGAGCCGCTTCCTGTTCAAGCCGGTGGCGCAGGTCATCGCGCAGCGCCGTGCCGAGATCGAGAAGCTGGTGGAGGATGCGCGCGCCGCCAAGGCCGCCGCCGAGGCCGAGCGGGACACGGCGAAGGCGGAGGAGGCGCGCCTTGCCGCCGAGCGCGGCGCCCGCATGGCGGCGGTCGCCAAGGAGGCGGAGGCGCAGAAGGCGGCATTGCTGGCCGCCGCCAAGACCGAGGCCGAGGCCCTGCACGCGGCCGCGGAAGCGGCCATCGTCCGGGCGCGGGCGAGCGAGGAGGAAGCCGCCGCCGACCGCGCCAGCCGCCTTGCCGTGGACATCGCCGCCAAGCTGCTGGACCGGCTGCCCGACGACGCCCGGGTCGCGGGCTTCATCGATGGCCTCGCCGAGGGGCTTGAAGCCCTGCCCGAGGCGAGCCGGGCGGTGATCGGCGTCGACGGCGCGCCAGTGCGCGTGACGGCCGCGCGCGCCCTTATGCCGGCGGAGGAGGAGGCCTGCCGCACGCGGCTCTCCCAGGCGCTGGGCCGTCCGGTGACGCTGGCCGTGACCATCGACCCCGCCCTCATCGCCGGCCTGGAGATGGAGACGCCCCACGCGGTGGTGCGCAATTCCTTCAAGGCCGATCTCGACCGCGTCACCGCGGCGCTCACCCATCATGGGACCTGA

[0104] [SEQ ID NO:23: Amino acid sequence of ATP synthase subunit b atpF_1] MQIDWWTLGLQTVNVLVLIWLLSRFLFKPVAQVIAQRRAEIEKLVEDARAKAAAEAERDTAKAEEARLAAERGARMAAVAKEAEAQKAALLAAAKTEAEALHAAAEAAIVRARASEEEAAAD RASRLAVDIAAKLLDRLPDDARVAGFIDGLAEGLEALPEASRAVIGVDGAPVRVTAARALMPAEEEACRTRLSQALGRPVTLAVTIDPALIAGLEMETPHAVVRNSFKADLDRVTAALTHHGT

[0105] [SEQ ID NO:24: Nucleotide sequence of ATP synthase subunit c, sodium ion specificity atpE_1] ATGACTGTCGAGATGGTCAGCATCTTCGCGGCGGCGCTCGCCGTCTCCTTCGGCGCCATCGGGCCGGCCCTGGGCGAGGGCCGGGCGGTGGCCGCGGCCATGGACGCCATCGCCGCCAGC CGGAGGCGGCCGGAACCTTGTCGCGCACGCTCTTCGTCGGCCTCGCCATGATCGAGACCATGGCGATCTACTGCCTGGTGATCGCGCTCCTGGTGCTCTTCGCCAATCCGTTCGTGAAGTGA

[0106] [SEQ ID NO:25: Amino acid sequence of ATP synthase subunit c, sodium ion specificity atpE_1] MTVEMVSIFAAALAVSFGAIGPALGEGRAVAAAMDAIARQPEAAGTLSRTLFVGLAMIETMAIYCLVIALLVLFANPFVK

[0107] [SEQ ID NO:26: Nucleotide sequence of ATP synthase subunit a atpB_1] ATGGGCTCGCCGCTGATCCTCGAACCCCTGTTCCATATCGGGCCCGTGCCCATCACCGCGCCGGTGGTGGTCACCTGGCTCATCATGGCCGCCTTCATTGGGCTGGCGCGGCTCATCACCCGGAAGCTTTCCACCGATCCCACCCGGACCCAGGCGGCGGTGGAAACGGTGCTGACCGCCATCGATTCCCAGATCGCCGACACCATGCAGGCCGATCCCGCGCCTTATCGCGCGCTCATCGGCACCATCTTCCTTTATGTGCTGGTGGCCAACTGGTCCTCGCTCATCCCGGGCATCGAGCCGCCCACGGCGCATATCGAGACCGATGCGGCGCTCGCTTTCATCGTGTTCGCCGCCACCATCGGGTTCGGGTTGAAGACAAGGGGTGTGAAGGGCTATCTCGCCACCTTCGCCGAACCCTCCTGGGTGATGATCCCGCTCAATGTGGTGGAGCAGATCACCCGGACCTTCTCGCTCATCGTGCGCCTGTTCGGCAACATCATGAGCGGGGTGTTCGTGGTCGGCATCATCCTGTCCCTCGCCGGGCTGCTGGTGCCCATCCCCCTCATGGCGCTCGATCTCCTGACCGGCGCCGTGCAGGCCTACATCTTCGCGGTGCTGGCCTGCGTGTTCATCGGCGCGGCCATTGGCGAGGCGCCGGCAAAGCCCCAATCGAAGGAGCCAGGGAAAACATCATGA

[0108] [SEQ ID NO:27: Amino acid sequence of ATP synthase subunit a atpB_1] MGSPLILEPLFHIGPVPITAPVVVTWLIMAAFIGLARLITRKLSTDPTRTQAAVETVLTAIDSQIADTMQADPAPYRALIGTIFLYVLVANWSSLIPGIEPPTAHIETDAALAFIV FAATIGFGLKTRGVKGYLATFAEPSWVMIPLNVVEQITRTFSLIVRLFGNIMSGVFVVGIILSLAGLLVPIPLMALDLLTGAVQAYIFAVLACVFIGAAIGEAPAKPQSKEPGKTS

[0109] [SEQ ID NO:28: Nucleotide sequence of atpC_1, ATP synthase epsilon chain] GTGAGCGCGCCGCTGCACCTCACCATCACCACGCCGGCCGCCGTTCTGGTGGACCGTGCCGACATCGTGGCCCTGCGTGCCGAGGACGAGAGCGGCAGCTTCGGCATCCTGCCCGGCCATGCGGATTTCCTGACCGTTCTGGAGGCCTGCGTGGTGCGCTTCAAGGATGGGGCCGACGGCGTGCATTATTGTGCTCTCAGTGGTGGCGTGCTGTCGGTCGAGGAGGGC CGGCGCATCGCCATCGCCTGCCGTCAGGCACGGTGAGCGACGACCTGGTCGCCCTGGAAGGGGCGGTGGACGCCATGCGTTCGGCGGAGAGCGATGCCGACAAGCGGGCCCGGGTGGAGCAGATGCGCCTTCATGCCCACGCCGTGCGCCAGCTCCTGCACTATCTGCGGCCCGGCCGGGCCGGCGGCGTGGCGCCGGCCGCCGCGCCGGAGGAGGGGCCGTCATGA

[0110] [SEQ ID NO:29: Amino acid sequence of ATP synthase epsilon chain atpC_1] MSAPLHLTITTPAAVLVDRADIVALRAEDESGSFGILPGHADFLTVLEACVVRFKDGADGVHYCALSGGVLSVEEGRRIAIACRQGTVSDDLVALEGAVDAMRSAESDADKRARVEQMRLHAHAVRQLLHYLRPGRAGGVAPAAAPEEGPS

[0111] [SEQ ID NO:30: Nucleotide sequence of ATP synthase subunit beta atpD_1]

[0112] [SEQ ID NO:31: Amino acid sequence of ATP synthase subunit beta atpD_1] MAAADEEAQSAAGPASGRVVAVRGAVIDIAFAQPPLPPLDDALLITDGRGGTVLVEVQSHMDRHTVRAIALQATTGLSRGLEAARVGGPVKVPVGDHVLGRLLDVTGAIGDKGGPLPADVPTRP IHHAPPSFAAQGGTSDLFRTGIKVIDLLAPLAQGGKAAMFGGAGVGKTVLVMELIHAMVASYKGISVFAGVGERSREGHEMLLDMTDSGVLDRTVLVYGQMNEPPGARWRVPMTALTIAEYFRD EKHQNVLLLMDNIFRFVQAGAEVSGLLGRPPSRVGYQPTLASEVAALQERITSVGEASVTAIEAVYVPADDFTDPAVTTIAAHVDSMVVLSRAMAAEGMYPAVDPISSSSVLLDPLIVGDEHAR VANEVRRTIEHYRELQDVISLLGMEELGTEDRRIVERARRLQRFLTQPFTVTEAFTGVPGRSVAIADTIAGCRMILSGACDDWQESALYMVGTIDEARQKEEAARAKAGQGAPAGTAAETAEAAP

[0113] [SEQ ID NO:32: Nucleotide sequence of ATP synthase subunit beta atpD_2]

[0114] [SEQ ID NO:33: Amino acid sequence of ATP synthase subunit beta atpD_2] MANKVGRITQIIGAVVDVQFDGHLPAILNAIETTNQGNRLVLEVAQHLGENTVRCIAMDATEGLVRGQEVADTDAPIQVPVGAATLGRIMNVIGEPVDELGPIEGEALRGIHQPAPSYA EQATEAEILVTGIKVVDLLAPYSKGGKVGLFGGAGVGKTVLIMELINNVAKAHGGYSVFAGVGERTREGNDLYHEMIESNVNKDPHENNGSAAGSKCALVYGQMNEPPGARARVALTGLT VAEHFRDQGQDVLFFVDNIFRFTQAGSEVSALLGRIPSAVGYQPTLATDMGQLQERITTTTKGSITSVQAIYVPADDLTDPAPAASFAHLDATTVLSRSIAEKGIYPAVDPLDSTSRML SPAILGDEHYNTARQVQQTLQRYKALQDIIAILGMDELSEEDKLTVARARKIERFLSQPFHVAEVFTGSPGKLVDLADTIKGFKGLVDGKYDYLPEQAFYMVGTIEEAIEKGKKLAAEAA

[0115] [SEQ ID NO:34: Nucleotide sequence of ATP synthase subunit gamma chain atpG_2] ATGGCGAGTCTGAAGGACCTGAGAAACCGCATTGCCTCGGTGAAGGCGACGCAGAAGATCACCAAGGCGATGCAGATGGTCGCCGCGGCGAAGCTGCGTCGCGCCCAGGCGGCGGCTGAAGCGGCCCGTCCCTATGCGGAACGCATGGAGACGGTGCTCGGAAATCTTGCCTCCGGCATGGTGGTGGGCGCGCAGGCGCCTGTTCTCATGACCGGGACGGGCAAGAGCGACACCCACCTGCTGCTGGTGTGCACCGGCGAGCGCGGCCTGTGCGGCGCCTTCAACTCGTCCATCGTGCGCTTCGCCCGCGAGCGGGCGCAGCTGCTGCTGGCCGAGGGCAAGAAGGTGAAAATCCTGTGCGTGGGCCGCAAGGGCCACGAGCAGCTGCGCCGCATCTACCCGGACAACATCATCGACGTGGTGGACCTGCGCGCGGTGCGCAACATCGGCTTCAAGGAGGCCGACGCCATCGCCCGCAAGGTGCTGGCCCTGCTCGATGAAGGCGCATTCGACGTCTGCACGCTCTTCTACTCCCACTTCAGGAGCGTGATCGCCCAGGTGCCGACGGCCCAGCAGCTCATTCCGGCCACCTTCGACGAGCGGCCGGCCGTCGCCGATGCGCCGGTCTATGAATATGAGCCGGAGGAGGAGGAGATCCTCGCCGAGCTGCTGCCGCGCAACGTGGCGGTGCAGATCTTCAAGGCCCTCCTCGAGAACCAGGCTTCTTTCTATGGCTCCCAGATGAGCGCCATGGACAACGCCACGCGCAATGCGGGCGAGATGATCAAGAAGCAGACGCTCACCTACAACCGTACCCGCCAGGCCATGATCACGAAGGAACTCATCGAGATCATCTCCGGCGCCGAGGCCGTCTGA

[0116] [SEQ ID NO:35: Amino acid sequence of ATP synthase subunit gamma chain atpG_2] MASLKDLRNRRIASVKATQKITKAMQMVAAAKLRRAQAAAEAARPYAERMETVLGNLASGMVVGAQAPVLMTGTGKSDTHLLLVCTGERGLCGAFNSSIVRFARERAQLLLAEGKKVKILCVGRKGHEQLRRIYPDNIIDVVDLRA VRNIGFKEADAIARKVLALLDEGAFDVCTLFYSHFRSVIAQVPTAQQLIPATFDERPAVADAPVYEYEPEEEEILAELLPRNVAVQIFKALLENQASFYGSQMSAMDNATRNAGEMIKKQTLTYNRTRQAMITKELIEIISGAEAV

[0117] [SEQ ID NO:36: Nucleotide sequence of ATP synthase subunit alpha atpA_2]

[0118] [SEQ ID NO:37: Amino acid sequence of ATP synthase subunit alpha atpA_2] MDIRAAEISAILKEQIQNFGQEAEVSEVGQVLSVGDGIARVYGLDNVQAGEMVEFENGTRGMALNLELDNVGIVIFGSDREIKEGQTVKRTGAIVDAPVGKGLLGRVVDALGNPIDGKGPIMFTERR RVDVKAPGIIPRKSVHEPMQTGLKAIDALIPIGRGQRELIIGDRQTGKTAVALDSILNQKPINQGDDEKAKLYCVYVAVGQKRSTVAQFVKVLEEHGALEYSIVVAATASDAAPMQFLAPFTGTAMG EYFRDNGMHALIIHDDLSKQAVAYRQMSLLLRRPPGREAYPGDVFYLHSRLLERAAKLNDEHGAGSLTALPVIETQANDVSAYIPTNVISITDGQIFLESDLFYQGIRPAVNVGLSVSRVGSSAQIK AMKQVAGKIKGELAQYRELAAFAQFGSDLDAATQKLLNRGARLTELLKQSQFSPLKVEEQVAVIYAGTNGYLDPLPVSKVREFEQGLLLSLRSQHPEILDAIRTSKELSKDTAEKLTKAIDAFAKSFS

[0119] [SEQ ID NO:38: Nucleotide sequence of ATP synthase subunit delta atpH] GTGGCGGAAACGATCGTGTCAGGCATGGCGGGACGCTATGCGACCGCGCTGTTCGAGCTGGCGGACGAAGCCGGTGCCATCGATTCCGTCCAGGCGGATCTTGATCGCCTGTCCGGCCTTCTGGCCGAGAGCGCGGAT CTGGCGCGGCTGGTCAAGAGCCCGGTCTTCACCGCCGAGCAGCAGCTCGGCGCGATGGCGGCCATTCTCGATCAAGCAGGCATTTCCGGCCTTGCGGGCAAATTCGTGAAGCTGGTGGCGCAGAACCGCCGCCTGTTCG CACTGCCGCGCATGATTGCCGAATACGCCGTCCTGGTGGCCCGGAAGAAGGGCGAGACCTCGGCGAGCGTGACCGTTGCCACCCCCCTGAGCGATGAGCATCTGGCCACGCTCAAGGCGGCCCTGGCTGAAAAGACCGG CAAGGACGTGAAGCTCGACGTCACCGTCGATCCGTCCATCCTCGGTGGTCTCATCGTGAAGCTCGGCTCGCGCATGGTCGATGCTTCCCTGAAGACCAAACTCAATTCTATCCGGCATGCGATGAAAGAGGTCCGCTGA

[0120] [SEQ ID NO:39: Amino acid sequence of ATP synthase subunit delta atpH] MAETIVSGMAGRYATALFELADEAGAIDSVQADLDRLSGLLAESADLARLVKSPVFTAEQQLGAMAAILDQAGISGLAGKFVKLVAQNRRLFALPRMIAEYAVLVARKKGETSASVTVATPLSDEHLATLKAALAEKTGKDVKLDVTVDPSILGGLIVKLGSRMVDASLKTKLNSIRHAMKEVR

[0121] [SEQ ID NO: 40: Nucleotide sequence of ATP synthase subunit b atpF_2] ATGACCGAAATGGAACTGGCTGAGCTCTGGGTCGCCATCGCCTTCCTGGTTTTCGTAGGCCTCCTGATCTATGCGGGCGCCCACCGCGCCATCGTCTCCGCCCTGGATTCCCGCGGCTCGCGC ATCGCCTCGGAACTGGAGGAGGCCCGTCGGCTCAAGGAAGAGGCCCAGAAGCTGGGTGGCCGAATTCAAGCGCAAGCAGCGCGAGGCCGAGGCCGAGGCCGAATCCATCGTCACCGGCGCCAAG GCCGAGGCCGAGCGCCTCGCCGCCGAGGCCAAGGCGAAGATCGAGGATTTCGTCACCCGCCGCACCAAGATGGCCGAGGACAAGATCGCCCAGGCCGAGCATCAGGCTCTGGCGGACGTGAAG TCCATCGCCGCCGAGGCGGCGGCCAAGGCGGCCGAGGTGATCCTCGGCGCCCAGGCCACCGGCGCGGTGGCGGAGCGTCTGCTGTCGGGCGCCATCTCCGAGGTCAAGACCAAGCTCAACTGA

[0122] [SEQ ID NO: 41: Amino acid sequence of ATP synthase subunit b atpF_2] MTEMELAELWVAIAFLVFVGLLIYAGAHRAIVSALDSRGSRIASELEEARRLKEEAQKLVAEFKRKQREAEAEAESIVTGAKAEAERLAAEAKAKIEDFVTRRTKMAEDKIAQAEHQALADVKSIAAEAAAKAAEVILGAQATGAVAERLLSGAISEVKTKLN

[0123] [SEQ ID NO: 42: Nucleotide sequence of ATP synthase subunit b' atpG_3] ATGATGATTGCATGGAAGCGGACCTTCGCAGTCGTGACCTTCGGGGCCGCCCTGATGGCCATGCCCGTCGCGGGCGTGGTCGCAGCTGAGACTTCTCCCGCTCCGGCGGCAGTGGCGCAGGCCGATCATGCGGTGCCCACCGAGGCGGCCGGCCAGGGCACCGCCGATGCGGCCCATGCCGCCGCGCCGGGCGAGGCCGCCCATGGTGGCGCGGCCAAGCACGAAACCCATTTCCCGCCCTTCGACGGCACCACCTTCGCCTCCCAGTTGCTGTGGCTCGCCGTCACCTTCGGCCTGCTTTACTACCTCATGAGCAAGGTCACGCTGCCGCGCATCGGCCGCATCCTGGAAGAGCGCCACGACCGCATCGCCGATGATCTGGAGGAAGCCTCCAAGCATCGCGCCGAGAGCGAGGCCGCCCAGCGGGCCTATGAGAAGGCGCTGAGCGAGGCCCGCGCGAAGGCCCATTCCATCGCCGCGGAAACCCGCGACCGCCTTGCCGCCCACGCCGACACCAACCGCAAGGCGCTGGAGAGCGAGCTCACCGCCAAGCTGCAGGCGGCCGAGGAGCGCATCGCCACCACCAAGAGCGAAGCCCTCACCCATGTGCGCGGCATCGCGGTGGACGCCACCCAATCCATCGTCTCCACCCTCATCGGTGTCGCGCCCGCGGCGGCCGACGTGGAAAAAGCGGTGGACGGCGCCCTGTCCCAGCACGGCCAGGCCTGA

[0124] [SEQ ID NO:43: Amino acid sequence of ATP synthase subunit b' atpG_3] MMIAWKRTFAVVTFGAALMAMPVAGVVAAETSPAPAAVAQADHAVPTEAAGQGTADAAHAAAPGEAAHGGAAKHETHFPPFDGTTFASQLLWLAVTFGLLYYLMSKVTLPRIGRILEERHD RIADDLEEASKHRAESEAAQRAYEKALSEARAKAHSIAAETRDRLAAHADTNRKALESELTAKLQAAEERIATTKSEALTHVRGIAVDATQSIVSTLIGVAPAAADVEKAVDGALSQHGQA

[0125] [SEQ ID NO: 44: Nucleotide sequence of ATP synthase subunit c atpE_2] ATGGAAGCGGAAGCTGGAAAGTTCATCGGTGCCGGCCTCGCCTGCCTCGGCATGGGTCTCGCTGGCGTCGGCGTCGGTAACATCTTCGGTAACTTCCTCTCCGGCGCCCTGCGCAACCCGTCCGCTGCCGACGGCCAGTTCGCCCGCCTTCATCGGCGCCGCCCTCGCGGAAGGTCTCGGCATCTTCTCGCTGGTCGTTGCGCTCGTCCTGCTGTTCGTGGCCTGA

[0126] [SEQ ID NO: 45: Amino acid sequence of ATP synthase subunit c atpE_2] MEAEAGKFIGAGLACLGMGLAGVGVGNIFGNFLSGALRNPSAADGQFARAFIGAALAEGLGIFSLVVALVLLFVA

[0127] [SEQ ID NO: 46: Nucleotide sequence of ATP synthase subunit a atpB_2] ATGACCGTCGATCCGATCCACCAGTTCGAGATCAAGCGCTACGTGGATCTGCTGAACGTCGGCGGTGTCCAGTTCTCCTTCACCAACGCAACGGTGTTCATGATTGGCATCGTCCTGGTGATTTTCTTCTTCCTGACTTTCGCGACACGCGGTCGCACCCTTGTGCCGGGCCGGATGCAGTCGGCGGCGGAGCTGAGCTACGAGTTCATCGCCAAGATGGTGCGCGACGCGGCCGGCAGCGAGGGAATGGTGTTCTTTCCCTTCGTCTTCTCGCTCTTCATGTTCGTGCTGGTGGCGAACGTATTGGGGCTCATCCCCTACACCTTCACGGTGACCGCCCACCTCATCGTCACCGCCGCCCTGGCGGCGACGGTGATCCTCACCGTCATCATCTACGGCTTCGTGCGGCACGGCACCCACTTCCTGCACCTGTTCGTGCCGTCGGGCGTGCCGGGCTTCCTCCTGCCCTTCCTCGTGGTGATCGAGGTGGTGTCGTTCCTGTCGCGGCCCATCAGCCTCTCGCTGCGTCTGTTCGCCAACATGCTGGCGGGCCACATCGCCCTCAAGGTGTTCGCCTTCTTCGTCGTGGGACTGGCCTCGGCCGGCGCGATCGGCTGGTTCGGCGCCACCCTGCCCTTCTTCATGATCGTGGCGCTCACCGCGCTGGAGCTGCTGGTGGCGGTGCTGCAGGCCTACGTGTTCGCGGTGCTGACCTCGATCTACCTCAACGACGCCATCCATCCCGGCCACTGA

[0128] [SEQ ID NO:47: Amino acid sequence of ATP synthase subunit a atpB_2] MTVDPIHQFEIKRYVDLLNVGGVQFSFTNATVFMIGIVLVIFFFLTFATRGRTLVPGRMQSAAELSYEFIAKMVRDAAGSEGMVFFPFVFSLFMFVLVANVLGLIPYTFTVTAHLIVTAALAATV ILTVIIYGFVRHGTHFLHLFVPSGVPGFLLPFLVVIEVVSFLSRPISLSLRLFANMLAGHIALKVFAFFVVGLASAGAIGWFGATLPFFMIVALTALELLVAVLQAYVFAVLTSIYLNDAIHPGH

[0129] [SEQ ID NO: 48: Nucleotide sequence of ATP synthase protein I (atpI)] ATGTCCGAGCCGAATGATCCATCCCGCAGGGACGGTGCGAAGGCGAAAGACGAGACGCAGGACTCCCGGCCCGGTGAGGCGGATCTTGCTCGGCGCCTCGATGCGCTCGGCACCTCCATCGGTCAGGTCAAGTCCAGAAGCGGGGAGCCCGCGGCGACGCCGCGCAAGGACACCTCCTCGCCTCCGGCGCGGCC CTGGCGTTTCGGCTGGGCGCCGAGTTTGTTTCAGGCGTGCTGGTGGGCTCGCTCATCGGCTACGGGTTGGATTATGCGTTTGCGATTTCGCCCTGGGGGCTGATCGCCTTCACGCTGATCGGCTTTGCCGCCGGCGTCCTGAACATGCTGCGCGTGGCGAACAGCGATGCCAAGCGCCACAGCGCGGACAGGTGA

[0130] [SEQ ID NO:49: Amino acid sequence of ATP synthase protein I (atpI)] MSEPNDPSRRDGAKAKDETQDSRPGEADLARRLDALGTSIGQVKSRSGEPAATPRKDTSSASGAALAFRLGAEFVSGVLVGSLIGYGLDYAFAISPWGLIAFTLIGFAAGVLNMLRVANSDAKRHSADR

[0131] In another embodiment, the bacterial strain used in the method of the present invention includes a gene encoding nitrogenase molybdenum-iron protein alpha chain nifD_1 having the sequence shown in SEQ ID NO: 51, or a sequence having more than 60% identity to the sequence shown in SEQ ID NO: 51, such as more than 70%, more than 92%, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0132] In another embodiment, the bacterial strain used in the method of the present invention includes a gene encoding nitrogenase molybdenum-iron protein alpha chain nifD_2 having the sequence shown in SEQ ID NO: 53, or a sequence having more than 60% identity to the sequence shown in SEQ ID NO: 53, such as more than 98% identity or more than 99% identity.

[0133] In another embodiment, the bacterial strain used in the method of the present invention includes a gene encoding nitrogenase molybdenum-iron protein beta chain nifK_1 having the sequence shown in SEQ ID NO: 55, or a sequence having more than 87% identity to the sequence shown in SEQ ID NO: 55, such as more than 90%, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0134] In another embodiment, the bacterial strain used in the method of the present invention includes a gene encoding nitrogenase molybdenum-iron protein beta chain nifK_2 having the sequence shown in SEQ ID NO: 57, or a sequence having more than 95% identity to the sequence shown in SEQ ID NO: 57, for example more than 96%, for example more than 97%, for example more than 98%, for example more than 99%.

[0135] In another embodiment, the bacterial strain used in the method of the present invention includes a gene encoding the nitrogenase iron protein nifH having the sequence shown in SEQ ID NO: 59, or a sequence having more than 98.5% identity to the sequence shown in SEQ ID NO: 59.

[0136] [SEQ ID NO:50: Nucleotide sequence of nitrogenase molybdenum-iron protein alpha chain nifD_1]

[0137] [SEQ ID NO:51: Amino acid sequence of nitrogenase molybdenum-iron protein alpha chain nifD_1] MSSLSATIQQVFNEPGCAKNQNKSEAEKKKGCTKQLQPGGAAGGCAFDGAKIALQPLTDVAHLVHGPIACEGNSWDNRGAKSSGSNIWRTGFTTDINETDVVFGGEKRLFKSIKEIIEKYDPPAVFVYQTCVPAMIGDDIDAVCKAAREKFGKPVIPINS PGFVGPKNLGNKLAGEALLDHVIGTEEPDYTTAYDINIIGEYNLSGELWQVKPLLDELGIRILACISGDGKYKDVASSHRAKAAMMVCSKAMINVARKMEERYDIPFFEGSFYGIEDSSDSLREIARMLIEKGADPELMDRTEALIEREEKKAWDAIAAYK PRFKDKKVLLITGGVKSWSVVAALQEAGLELVGTSVKKSTKEDKERIKELMGQDAHMIDDMTPREMYKMLKDAKADIMLSGGRSQFIALKAAMPWLDINQERHHAYMGYVGMVKLVEEIDKALYNPVWEQVRKPAPWENPEDTWQARALAEMEAEAAALA ADPVRAEEVRRSKICNCKSVDLGTIEDAIKAHALTTVEGVREHTNASGGCGACSGRIEEIFEAVGVVAAPPPAEAAPSPQEIAPDPLAAEEKRRAKKACGCKEVGTIEDAIRAKGLRNIAEVRAATDANTGCGNCQERVEGILDRVLAEAASELQAAE

[0138] [SEQ ID NO:52: Nucleotide sequence of nitrogenase molybdenum-iron protein alpha chain nifD_2]

[0139] [SEQ ID NO: 53: Amino acid sequence of nitrogenase molybdenum-iron protein alpha chain nifD_2] MSVAQSQSVAEIKARNKELIEEVLKVYPEKTAKRRAKHLNVHEAGKSDCGVKSNIKSIPGVMTIRGCAYAGSKGVVWGPIKDMIHISHGPVGCGQYSWAARRNYYIGTTGIDTFVTMQFTSDFQE KDIVFGGDKKLAKIMDEIQELFPLNNGITVQSECPIGLIGDDIEAVSKQKSKEYEGKTIVPVRCEGFRGVSQSLGHHIANDAIRDWVFDKIAPDAEPRFEPTPYDVAIIGDYNIGGDAWSSRILL EEMGLRVIAQWSGDGSLAELEATPKAKLNVLHCYRSMNYISRHMEEKYGIPWCEYNFFGPSKIAESLRKIASYFDDKIKEGAERVIAKYQPLMDAVIAKYRPRLEGKTVMLYVGGLRPRHVIGAY EDLGMEVVGTGYEFAHNDDYQRTAQHYVKDGTIIYDDVTGYEFEKFVEKIQPDLVGSGIKEKYVFQKMGVPFRQMHSWDYSGPYHGYDGFAIFARDMDMAINSPVWKMTQAPWKSVPKPTMLAAE

[0140] [SEQ ID NO:54: Nucleotide sequence of nitrogenase molybdenum-iron protein beta chain nifK_1]

[0141] [SEQ ID NO: 55: Amino acid sequence of nitrogenase molybdenum-iron protein beta chain nifK_1] MATVSVSKKACAVNPLKMSQPVGGALAFMGVRKAMPLLHGSQGCTSFGLVLFVRHFKEAIPMQTTAMSEVATVLGGLENVEQAILNIYNRTKPEIIGICSTGVTETKGDDVDGY IKLIRDKYPQLADFPLVYVSTPDFKDAFQDGWEKTVAKMVEALVKPAADKQKDKTRVNVLPGCHLTPGDLDEMRTIFEDFGLTPYFLPDLAGSLDGHIPEDFSPTTIGGIGIDEI ATMGEAAHTICIGAQMRRAGEAMEKKTGIPFKLFERLCGLEANDAFIMHLSQISGRPVPVKYRRQRGQLVDAMLDGHFHLGGRKVAMGAEPDLLYDVGSFLHEMGAHILSAVTT TQSPVLARLPAEEVLIGDLEDLETQAKARGCDLLLTHSHGRQAAERLHIPFYRIGIPMFDRLGAGHLLSVGYRGTRDLIFHLANLVIADHEENHEPTPDTWATGHGEHAAAPTSH

[0142] [SEQ ID NO:56: Nucleotide sequence of nitrogenase molybdenum-iron protein beta chain nifK_2]

[0143] [SEQ ID NO: 57: Amino acid sequence of nitrogenase molybdenum-iron protein beta chain nifK_2] MPQNADNVLDHFELFRGPEYQQMLANKKKMFENPRDPAEVERVREWAKTPEYKELNFAREALTVNPAKACQPLGAVFVAVGFESTIPFVHGSQGCVAYYRSHLSRHFKEPSSCVSSSMTEDAAVFGGLN NMIDGLANTYNMYKPKMIAVSTTCMAEVIGDDLNAFIKTAKEKGSVPAEYDVPFAHTPAFVGSHVTGYDNALKGILEHFWDGKAGTAPKLERVPNEKINFIGGFDGYTVGNTREVKRIFEAFGADYTILA DNSEVFDTPTDGEFRMYDGGTTLEDAANAVHAKATISMQEYCTEKTLPMIAGHGQDVVALNHPVGVGGTDKFLMEIARLTGKEIPEELTRERGRLVDAIADSSAHIHGKKFAIYGDPDLCLGLAAFLLEL GAEPTHVLATNGTKKWAEKVQELFDSSPFGANCKVYPGKDLWHMRSLLFVEPVDFIIGNTYGKYLERDTGTPLIRIGFPVFDRHHHHRRPVWGYQGGMNVLITILDKIFDEIDRNTNVPAKTDYSFDIIR

[0144] [SEQ ID NO: 58: Nucleotide sequence of nitrogenase iron protein nifH] GTGGAGTCCGGTGGTCCTGAGCCGGGCGTGGGCTGCGCCGGCCGCGGCGTGATCACCTCCATCAACTTCCTGGAGGAGAACGGCGCCTACGAGGACATCGACTATGTGTCCTACGACGTGCTGGGCGACGTGGTGTGCGGCGGCTTCGCCATGCCCATCCGCGAGAACAAGGCGCAGGAAATCTACATCGTGATGTCCGGCGAGATGATGGCCATGTATGCGGCCAACAACATCTCCAAGGGCATCCTGAAGTATGCCAATTCCGGCGGCGTGCGCCTGGGCGGGCTGGTCTGCAACGAGCGCCAGACCGACAAGGAGCTGGAGCTGGCGGAGGCTCTGGCGAAGAAGCTCGGCACCGAGCTGATCTACTTCGTGCCGCGCGACAACATCGTGCAGCATGCCGAGCTGCGCCGCATGACAGTGATCGAGTATGCGCCCGATTCCGCCCAGGCCCAGCACTACCGGAACCTGGCCGAGAAGGTGCACGCCAACAAGGGCAACGGCATCATCCCGACCCCGATCACCATGGACGAGCTGGAAGACATGCTCATGGAGCACGGCATCATGAAGGCCGTGGACGAGAGCCAGATCGGCAAGACCGCCGCCGAGCTCGCCGTCTGA

[0145] [SEQ ID NO:59: Amino acid sequence of nitrogenase iron protein nifH] MESGGPEPGVGCAGRGVITSINFLEENGAYEDIDYVSYDVLGDVVCGGFAMPIRENKAQEIYIVMSGEMMAMYAANNISKGILKYANSGGVRLGGLVCNERQTDKELELAEALAKKLGTELIYFVPRDNIVQHAELRRMTVIEYAPDSAQAQHYRNLAEKVHANKGNGIIPTPITMDELEDMLMEHGIMKAVDESQIGKTAAELAV

[0146] (Downstream process) In one embodiment, the method of the present invention includes a further step of harvesting the biomass produced during cultivation. The biomass may be harvested by, for example, sedimentation (gravity-based sedimentation), filtration, centrifugation, or flocculation. Flocculation may require the addition of a flocculant. Centrifugation may be carried out, for example, using a continuous flow centrifuge.

[0147] In one embodiment, the harvested biomass is subsequently dried. Drying can be carried out using known methods, such as centrifugation, drum drying, evaporation, freeze-drying, heating, spray drying, vacuum drying, and / or vacuum filtration. The dried biomass can then be used in products, such as food or feed products, or feed or food components.

[0148] In another embodiment, the cells of the harvested biomass are lysed. In some embodiments, the lysate can be separated into an insoluble fraction and a soluble fraction, either or both of which can then be concentrated or dried and used in products such as food or feed products.

[0149] In one embodiment, biomass is harvested, and proteins are isolated from the biomass to obtain a protein fraction and a fraction containing non-protein components. Thus, in one embodiment, the method is for the production of proteins and includes the steps of culturing strain VTT-E-193585 or a derivative thereof, followed by the steps of harvesting biomass and further isolating proteins from the biomass. In another embodiment, the method is for protein production and comprises culturing a strain of Xanthobacter bacteria in continuous culture using an inorganic carbon source including hydrogen and carbon dioxide as energy sources, followed by the steps of harvesting biomass and further isolating proteins from the biomass. Depending on the method of protein isolation, the resulting fraction can be either purer or less pure. Therefore, the term "protein fraction" refers to a fraction rich in protein. Even a protein fraction can contain significant amounts of other components, and a considerable amount of protein may ultimately be present in a "non-protein fraction."

[0150] Protein isolation may be carried out using any suitable method. For example, in one embodiment, the protein may be isolated using any suitable method, such as mechanically disrupting the cells and separating the protein from the cell fragments by one or more filtration steps, for example, by sequential filtration through multiple filters with decreasing pore size. Mechanical fracture can be carried out using methods such as ball milling, ultrasonic treatment, homogenization, high-pressure homogenization, and mechanical shearing. The resulting filtered protein fraction is rich in protein but also contains other, finer components. The protein can optionally be further purified from this fraction using appropriate methods.

[0151] In another embodiment, the protein fraction is isolated by performing ethanol extraction followed by one or more filtration steps. Such methods are known, for example, from the preparation of soybean protein (see, for example, Chapter 5, "Soybean Protein Concentrates," in "Technology of production of edible flours and protein products from soybeans" in Berk FAO Agricultural Services Bulletin No. 97 (1992)). The resulting filtered protein fraction is rich in protein but also contains other finer components. The protein can optionally be further purified from this fraction using appropriate methods.

[0152] In one embodiment, the method of the present invention includes a further step of hydrolyzing the protein fraction obtained from the method of the present invention to obtain amino acids and small peptides.

[0153] In one embodiment of the method of the present invention, the method includes a further step of producing a food or feed product from the biomass, the protein fraction, or a fraction containing non-protein components. The aforementioned further step may include simply incorporating the biomass, protein fraction, or non-protein component fraction into a food or feed product by adding it during the manufacturing of the food or feed product. In other embodiments, further purification or modification of biomass or fractions thereof is carried out during the process of its incorporation into food or feed products.

[0154] In a further aspect, the present invention relates to products such as biomass, proteins, or non-protein components that can be obtained or potentially obtained by the methods according to the present invention.

[0155] In one embodiment, the product obtained by the method of the present invention contains more than 40% protein, for example, protein between 40% and 99%, protein between 40% and 90%, or protein between 40% and 60%. In certain embodiments, the product contains between 25% and 75% protein, between 0% and 20% lipids, and between 5% and 40% carbohydrates. In a further embodiment, the product contains between 40% and 60% protein, between 0% and 15% lipids, and between 10% and 25% carbohydrates. In yet another embodiment, the product obtained by the method of the present invention contains between 45% and 55% protein, between 5% and 10% lipids, and between 10% and 20% carbohydrates.

[0156] As described above, further embodiments of the present invention relate to food or feed products that can be obtained or may be obtained by the method of the present invention. As used herein, the terms “food” and “feed” are intended to include not only conventional food and feed products such as processed foods, but also related products such as protein bars, powders or shakes, meat substitutes, food ingredients, probiotics, prebiotics, and other food and feed supplements. In certain embodiments, the biomass, the protein fraction, or the fraction containing non-protein components is used in the production of vegetarian or vegan foods.

[0157] The present invention is further illustrated by the following non-limiting embodiments. [Examples]

[0158] (Example 1) Isolation of bacterial strains capable of chemosynthetic autotrophic growth A 50 mL sample containing soil and seawater was collected in a sterile Falcon tube from the Baltic Sea coast in Naantali, Finland. A portion of the soil sample was mixed with 10 mL of mineral medium in a sterile Erlenmeyer flask. The culture medium was prepared by mixing 1 g / L NH4OH, 0.23 g / L KH2PO4, 0.29 g / L Na2HPO4·2H2O, 0.005 g / L NaVO3·H2O, 0.2 g / L FeSO4·7H2O, 0.5 g / L MgSO4·7H2O, 0.01 g / L CaSO4, 0.00015 g / L Na2MoO4·2H2O, 0.005 g / L MnSO4, 0.0005 g / L ZnSO4·7H2O, 0.0015 g / L H3BO3, 0.001 g / L CoSO4, 0.00005 g / L CuSO4, and 0.0001 g / L NiSO4 with tap water. The soil and culture medium suspensions were incubated in a sealed steel box continuously flushed with the following gas mixture in a shaking incubator at 30°C. Gas mixture: 150 mL / min of N2, 18 mL / min of H2, 3 mL / min of O2, and 6 mL / min of CO2. 1 mL of the suspension was added aseptically to 9 mL of culture medium in an Erlenmeyer flask, and the culture was renewed every 7 days before being returned to the incubation box. After the fourth dilution, no visible soil remained in the suspension. To grow biomass for bioreactor culture, the amount of cell suspension was increased to 100 mL. When inoculated into 190 mL of mineral medium in a 15-container 200 mL parallel bioreactor system (Medicel Explorer, Medicel Oy, Finland), the optical density (OD) of the suspension was measured. 600 The value was 1.53. The culture conditions were set to 800 rpm stirring, 30°C temperature, and pH 6.8 using 1M NaOH. A gas mixture of 14 mL / min of H2, 3 mL / min of O2, and 6 mL / min of CO2 was supplied through a separator. Air was flowed into the reactor headspace at 300 ml / min. Continuous culture was performed with a supply of mineral medium at 6 mL / h, and the cell suspension was aspirated from the reactor via a capillary to maintain a constant volume of 200 mL. The cell suspension withdrawn from the reactor was stored at 4°C. Samples were automatically collected daily from the bioreactor, and growth was monitored by measuring the absorbance at 600 nm. After 498 hours of bioreactor incubation, samples were aseptically collected, the suspension was diluted, and plated onto agar mineral medium plates containing the minerals described above and 2% bacterial agar. The plates were incubated under the same conditions as described above for the Erlenmeyer flask. Next, colonies were selected from the agar plate and streaked onto a new agar plate to isolate one organism from each colony. This was repeated twice. Single colonies were picked up and suspended in 200 μL of culture medium in a 96-well microtiter plate. The suspension was incubated at 30°C and shaken at 625 rpm in an EnzyScreen airtight box continuously flushed with 150 mL / min of N2, 18 mL / min of H2, 3 mL / min of O2, and 6 mL / min of CO2. The suspension was transferred from one well to an Erlenmeyer flask and replenished with fresh medium. The volume was increased until sufficient biomass was obtained for bioreactor culture. The organism was deposited in the VTT Culture Collection as VTT-E-193585.

[0159] 16S rRNA sequencing of the sample indicated that the sample contained only one organism. The same sample was used for Illumina NextSeq sequencing to provide a 1x150bp metagenomic shotgun sequence. A denovo assembly of the metagenomic sequence, consisting of 101 contigs, was constructed using Unicycler (Wick et al, 2017 PLoS Computational Biology 13:e1005595). The total genome length was 4,846,739 bp, and the GC content was 67.9%. Gene prediction and functional annotation were performed using Prokka (Seemann, 2014 Bioinformatics 30:2068). Genome annotation generated 4,429 genes. The Roary pan genome alignment (Page et al, 2015 Bioinformatics 31:3691) grouped VTT-E-193585 across xanthobacter species. Therefore, this strain was identified as Xanthobacter sp., and its closest genome was that of Xanthobacter tagetidis. Alignment-based average nucleotide identity calculations considering only orthologous fragments (OrthoANI) (Lee et al, 2016 Int J Syst Evol Microbiol 66:1100) showed the best agreement of 80.4% with Xanthobacter tagetidis (ATCC 700314; GCF_003667445.1). The proposed species boundary cutoffs were 95–96% (see, for example, Chun et al, 2018 Int J Syst Evol Microbiol, 68:461–466). Xanthobacter autotrophicus Py2 showed a 79.6% agreement rate, while Xanthobacter sp. 91 showed only 79.0%. Therefore, it could be concluded that the isolated bacterial strain deposited as VTT-E-193585 belongs to the phylum Proteobacteria, class Alpha Proteobacteria, and order Rhizobiales. The most likely family is Xanthobacteraceae, and the genus is Xanthobacter. The bacterial strain VTT-E-193585 could not be clearly assigned to a known species.

[0160] A search for presumed antibiotic resistance genes was conducted. Using the ABRicate tool (https: / / github.com / tseemann / abricate), genomes were searched against the Arg-Annot, NCBI, ResFinder, ecOH, Megares, and VFDB databases using blastn or blastp. A 50% threshold was set for both identity and coverage length at both the nucleotide and protein levels. Only two putative antibiotic resistance genes were identified. Since these two genes did not contain amino acid changes associated with antibiotic resistance, a resistance phenotype was not expected.

[0161] (Example 2) Pilot culture and analysis of isolated bacterial strains The isolated strain deposited as VTT-E-193585 was cultured in a conventional 200-liter agitated bioreactor (MPF-U, Marubishi, Japan). Mixing was performed using a Rushton-type impeller rotating at 400 rpm. The culture temperature was maintained at 30°C. pH was maintained at 6.8 ± 0.2 by adding 8M NaOH or 3.6MH3PO4 under software control. The culture medium was prepared by mixing 1 g / L NH4OH, 0.23 g / L KH2PO4, 0.29 g / L Na2HPO4·2H2O, 0.005 g / L NaVO3·H2O, 0.2 g / L FeSO4·7H2O, 0.5 g / L MgSO4·7H2O, 0.01 g / L CaSO4, 0.00015 g / L Na2MoO4·2H2O, 0.005 g / L MnSO4, 0.0005 g / L ZnSO4·7H2O, 0.0015 g / L H3BO3, 0.001 g / L CoSO4, 0.00005 g / L CuSO4, and 0.0001 g / L NiSO4 with tap water. A mixture containing 1.8–10.5 L / min of hydrogen gas, 0.6–2.5 L / min of oxygen gas, and 1.8–5 L / min of carbon dioxide gas was regularly supplied as the main energy and carbon source. The dissolved oxygen level was maintained at 7.2 ± 0.5% by adjusting the composition of the gas mixture. The inoculum for culture was prepared as described in Example 1. Cell growth was monitored by manually collecting samples and analyzing cell density as optical density by measuring absorbance at 600 nm (Ultrospec 2100 pro UV / Vis spectrophotometer, Biochrom Ltd., England), and by measuring cell dry weight (CDW) after drying overnight in an oven at 105°C. Optical density was also monitored using an appropriate absorbance probe (Trucell 2, Finesse Ltd, USA). The growth curve of the culture is shown in Figure 1. The maximum growth rate in the batch phase is 0.06h. -1 The maximum cell density was 4.5 g CDW / L after 92 hours. After 92 hours of incubation, supply fresh culture medium as described above for 0.01 hours. -1The culture was started at the following dilution ratio. During continuous feeding, the average cell density was 2.9 g_CDW / L. The culture medium was collected in a constantly cooled (10°C) tank and fed in 300-liter batches to a continuous centrifuge (BTPX-205, Alfa-Laval AB, Sweden). The cell-containing slurry collected from the separator was fed into an atmospheric pressure double-drum dryer (Buflovak 6x8 ADDD, Hebeler process solutions LLC, USA), heated with 4 bar steam, and the drums were rotated at 3.5 rpm. This resulted in a dried cell powder with a dry matter content of approximately 96%. The analysis results of the dried cell powder are shown in Table 1 for approximate composition, Table 2 for amino acid composition, Table 3 for fatty acid composition, and Table 4 for vitamin content. The analysis shows that the dried cell powder has a high protein content, containing all essential amino acids. It also contained more unsaturated fatty acids than saturated fatty acids, and a high amount of B vitamins. The peptidoglycan content was only 0.002 mg / g CDW, and the lipopolysaccharide content was 0.01 mg / g CDW. It would be beneficial to keep these concentrations as low as possible. In comparison, commercially available lactic acid bacteria preparations analyzed at the same time contained peptidoglycan at 0.244 mg / g DW and lipopolysaccharide at 0.015 mg / g DW. Cytotoxicity and genotoxicity assays were performed using culture supernatant samples. No cytotoxicity was observed against HepG2 or HeLa229 human cell lines. Escherichia coliWP2trp - Alternatively, no genotoxicity was observed against the CM871uvrArecAlexA strain.

[0162] [Table 1]

[0163] [Table 2]

[0164] [Table 3]

[0165] [Table 4]

[0166] (Example 3) Culture of bacterial strains isolated under different nitrogen sources The isolated bacterial strain deposited as VTT-E-193585 was cultured in a 15-container 200 mL parallel bioreactor system (Medicel Explorer, Medicel Oy, Finland). Mixing was performed using a Rushton-type impeller rotating at 800 rpm. The culture was maintained at a temperature of 30°C. The pH was maintained at 6.8 by adding 1M NaOH. The culture medium consisted of 0.23 g / L KH2PO4, 0.29 g / L Na2HPO4·2H2O, 0.005 g / L NaVO3·H2O, 0.2 g / L FeSO4·7H2O, 0.5 g / L MgSO4·7H2O, 0.01 g / L CaSO4, 0.00015 g / L Na2MoO4·2H2O, 0.005 g / L MnSO4, 0.0005 g / L ZnSO4·7H2O, 0.0015 g / L H3BO3, 0.001 g / L CoSO4, 0.00005 g / L CuSO4, and 0.0001 g / L NiSO4, prepared with tap water. Furthermore, the nitrogen sources were modified as follows: four cultures contained 18.7 mM NH4OH, four cultures contained 9.34 mM urea (OC(NH2)2), four cultures contained 18.7 mM potassium nitrate (KNO3), and three cultures had no nitrogen source in the medium. A mixture containing 22 mL / min of hydrogen gas, 3.2 mL / min of air, and 6.4 mL / min of carbon dioxide gas was periodically supplied as the main energy and carbon source. In addition to using air, nitrogen gas was also supplied to all cultivation. Growth was monitored by automatically collecting samples and analyzing cell density as optical density by measuring absorbance at 600 nm (Ultrospec 2100 pro UV / Vis spectrophotometer, Biochrom Ltd., UK). The growth curves of the cultures are shown in Figure 2. Growth was similar in ammonia and urea. Growth in nitrate or nitrogen gas was significantly slower than in ammonia or urea. Towards the end of the culture, growth in nitrate was better than growth in nitrogen gas as the sole nitrogen source. Nevertheless, growth was also observed in cultures where nitrogen gas was the sole nitrogen source, indicating that the isolated strain deposited as VTT-E-193585 is capable of nitrogen fixation.

[0167] (Example 4) Characteristics of antibiotic susceptibility The antibiotic susceptibility of the bacterial strain deposited as VTT-E-193585 to gentamicin, kanamycin, streptomycin, tetracycline, ampicillin, ciprofloxacin, colistin, and fosfomycin was measured according to the CLSI M07-A111 standard (Clinical Laboratory Standards Association; Method for Dilution Antimicrobial Susceptibility Testing of Aerobically Growing Bacteria, 11th Edition, CLSI Standard M07, 2018). For ampicillin, ciprofloxacin, and colistin, handmade microdilution plates are used; for gentamicin, kanamycin, streptomycin, and tetracycline, the broth microdilution method is used with VetMIC Lact-1 plates (SVA National Veterinary Institute, Uppsala, Sweden); and for fosfomycin, cation-adjusted Mueller-Hinton broth medium (LabM, LAB114, cation Mg 2 + and Ca 2 Measurements were taken using the agar dilution method under aerobic conditions of 35±2°C for 48±1 hours, with (+ added separately). Escherichia coli ATCC 25922 was used as a quality control strain and cultured under aerobic conditions at 35±2°C for 18±2 hours. The results of the antibiotic susceptibility of the strains are shown in Table 5. The isolated bacterial strains were generally found to be susceptible to antibiotics. The minimum inhibitory concentrations (MICs) of gentamicin, kanamycin, streptomycin, and tetracycline for VTT-E-193585 were lower than or equivalent to those of E. coli ATCC 25922, but the MICs for ampicillin, ciprofloxacin, colistin, and fosfomycin were higher than those of VTT-E-193585.

[0168] [Table 5]

Claims

1. An isolated bacterial strain VTT-E-193585 or a derivative thereof, The derivative is a bacterial strain that retains the ability to grow using hydrogen gas as an energy source and carbon dioxide as the sole carbon source. The derivative is the 16S ribosomal RNA shown in Sequence ID No. 1, or It contains 16S ribosomal RNA that differs from Sequence ID No. 1 by up to 20 nucleotides, The derivative is a bacterial strain having fewer than 10 genetic modifications.

2. A derivative of the isolated bacterial strain VTT-E-193585 described in claim 1, comprising the following: i) A gene encoding the ribulose-1,5-bisphosphate carboxylase / oxygenase (RuBisCO) large chain having the sequence of SEQ ID NO: 3, or a sequence having more than 93% identity to the sequence of SEQ ID NO:

3. and or, ii) A gene encoding a ribulose-1,5-bisphosphate carboxylase / oxygenase (RuBisCO) small chain having the sequence of Sequence ID No. 5, or a sequence having more than 83% identity to the sequence of Sequence ID No.

5. and or, iii) A gene encoding the NAD+ reducing hydrogenase HoxS subunit alpha having the sequence of Sequence ID No. 7, or a sequence having more than 70% identity with the sequence of Sequence ID No. 7, and or, iv) A gene encoding the NAD+ reducing hydrogenase HoxS subunit beta having the sequence of Sequence ID No. 9, or a sequence having more than 77% identity to the sequence of Sequence ID No. 9, and or, v) A gene encoding the NAD+ reducing hydrogenase HoxS subunit gamma having the sequence of SEQ ID NO: 11, or a sequence having more than 70% identity to the sequence of SEQ ID NO:

11. and or, vi) A gene encoding the NAD+ reducing hydrogenase HoxS subunit delta having the sequence of sequence number 13, or a sequence having more than 79% identity to the sequence of sequence number 13. and or, vii) A gene encoding a NiFeSe hydrogenase large subunit having the sequence of Sequence ID No. 15, or a sequence having more than 84% identity to the sequence of Sequence ID No.

15. and or, viii) A gene encoding a NiFeSe hydrogenase small subunit having the sequence of Sequence ID No. 17, or a sequence having more than 90% identity to the sequence of Sequence ID No. 17, and or, ix) A gene encoding the ATP synthase gamma chain atpG_1 having the sequence of sequence number 19, or a sequence having more than 70% identity to the sequence of sequence number 19. and or, x) A gene encoding the ATP synthase subunit alpha atpA_1 having the sequence of sequence number 21, or a sequence having more than 78% identity with the sequence of sequence number 21. and or, xi) A gene encoding the ATP synthase subunit b atpF_1 having the sequence of sequence number 23, or a sequence having more than 62% identity to the sequence of sequence number 23. and or, xii) The sequence of SEQ ID NO: 25, or a gene encoding ATP synthase subunit c, sodium ion specificity atpE_1, having a sequence that is more than 90% identical to the sequence of SEQ ID NO:

25. and or, xiii) A gene encoding ATP synthase subunit a atpB_1 having the sequence of sequence number 27, or a sequence having more than 80% identity with the sequence of sequence number 27, and or, xiv) A gene encoding the ATP synthase epsilon chain atpC_1 having the sequence of sequence number 29, or a sequence having more than 71% identity with the sequence of sequence number 29, and or, xv) A gene encoding ATP synthase subunit beta atpD_1 having the sequence of sequence number 31, or a sequence having more than 84% identity to the sequence of sequence number 31. and or, xvi) A gene encoding ATP synthase subunit beta atpD_2 having the sequence of sequence number 33, or a sequence having more than 97% identity to the sequence of sequence number 33. and or, xvii) A gene encoding the ATP synthase gamma chain atpG_2 having the sequence of sequence number 35, or a sequence having more than 86% identity to the sequence of sequence number 35. and or, xviii) A gene encoding the ATP synthase subunit alpha atpA_2 having the sequence of sequence number 37, or a sequence having more than 98% identity to the sequence of sequence number 37, and or, xix) A gene encoding the ATP synthase subunit delta atpH having the sequence of sequence number 39, or a sequence having more than 85% identity to the sequence of sequence number 39. and or, xx) A gene encoding the ATP synthase subunit b atpF_2 having the sequence of sequence number 41, or a sequence having more than 87% identity to the sequence of sequence number 41. and or, xxi) A gene encoding the ATP synthase subunit b' atpG_3 having the sequence of sequence number 43, or a sequence having more than 81% identity to the sequence of sequence number 43. and or, xxii) A gene encoding the ATP synthase subunit c atpE_2 having the sequence of sequence number 45, or a sequence having more than 98% identity to the sequence of sequence number 45, and or, xxiii) A gene encoding ATP synthase subunit a atpB_2 having the sequence of sequence number 47, or a sequence having more than 92% identity to the sequence of sequence number 47, and or, xiv) A gene encoding ATP synthase protein I atpI having the sequence of sequence number 49, or a sequence having more than 60% identity to the sequence of sequence number 49. and or, xv) A gene encoding the nitrogenase molybdenum-iron protein alpha chain nifD_1 having the sequence of sequence number 51, or a sequence having more than 60% identity to the sequence of sequence number 51. and or, xvi) A gene encoding the nitrogenase molybdenum-iron protein alpha chain nifD_2 having the sequence of sequence number 53, or a sequence having more than 60% identity to the sequence of sequence number 53. and or, xvii) The sequence of sequence number 55, or the gene encoding the nitrogenase molybdenum-iron protein beta chain nifK_1 having a sequence that is more than 87% identical to the sequence of sequence number 55, and or, xviii) The sequence of Sequence ID No. 57, or the gene encoding the nitrogenase molybdenum-iron protein beta chain nifK_2 having a sequence that is more than 95% identical to the sequence of Sequence ID No. 57, and or, xxix) A gene encoding nitrogenase iron protein nifH having the sequence of sequence number 59, or a sequence having more than 98.5% identity to the sequence of sequence number 59. Here, the aforementioned stock is, - The genes represented in iii), iv), v), and vi) above; - The genes represented in vii) and viiii) above; or, - The genes represented in iii), iv), v), vi), vii), and viiii) above, A bacterial strain that includes this strain.

3. A culture comprising the bacterial strain described in claim 1 or 2.

4. A method for biomass production, comprising culturing a bacterial strain which is a derivative according to claim 1 or 2.

5. This includes culturing bacterial strains in a continuous culture using hydrogen and an inorganic carbon source as energy sources. The method according to claim 4, wherein the inorganic carbon source includes carbon dioxide.

6. The method according to claim 4 or 5, wherein the dissolved oxygen in the culture is maintained between 5% and 10%.

7. The method according to any one of claims 4 to 6, wherein ammonium, urea, nitrate and / or nitrogen gas is used as the nitrogen source.

8. The culture medium contains minerals, The method according to any one of claims 4 to 7, wherein the mineral contains less than 1.0 g / L of chloride salt, or no chloride salt is supplied to the culture medium.

9. The method according to any one of claims 4 to 8, wherein the culture medium does not contain vitamins.

10. The method according to any one of claims 4 to 9, wherein the pH of the culture is maintained between 5.5 and 8.

0.

11. The method according to any one of claims 4 to 10, wherein the culture is grown at a temperature between 25°C and 40°C.

12. The method according to any one of claims 4 to 11, wherein the bacterial strain is grown at a rate of 0.04 to 0.12 per hour.

13. The method according to any one of claims 4 to 12, further comprising the step of harvesting the biomass produced during cultivation.

14. The method according to claim 13, further comprising a biomass drying step after the biomass harvesting step.

15. The method according to claim 13 or 14, further comprising the step of isolating the protein from the biomass, A method for producing protein, wherein a protein fraction and a fraction containing non-protein components are obtained by the method described above.

16. The method according to claim 15, further comprising the step of producing a food or feed product from the biomass, from the protein fraction, or from the fraction containing the non-protein component.

17. Biomass obtained by culturing the isolated bacterial strain VTT-E-193585 or a derivative thereof as described in claim 1, and harvesting the biomass produced during cultivation.

18. The biomass according to claim 17, obtained by harvesting the biomass and then drying the biomass.

19. Biomass comprising the bacterial strain described in claim 1 or 2.

20. The biomass according to claim 17 or 18, wherein the culture is carried out continuously using hydrogen gas as an energy source and carbon dioxide gas as an inorganic carbon source.

21. The biomass according to any one of claims 17 to 20, comprising protein between 40% and 99%.

22. The biomass according to any one of claims 17 to 20, comprising between 25% and 75% protein, between 0% and 20% lipid, and between 5% and 40% carbohydrates.

23. The biomass according to any one of claims 17 to 22, comprising all essential amino acids.

24. The biomass according to any one of claims 17 to 23, which contains more unsaturated fatty acids than saturated fatty acids.

25. The biomass according to any one of claims 17 to 24, comprising vitamin B1, vitamin B2, vitamin B3, vitamin B6, and vitamin B12.

26. A protein or protein fraction obtained by culturing the isolated bacterial strain VTT-E-193585 or a derivative thereof according to claim 1, harvesting the biomass produced during cultivation, and isolating the protein from the biomass.

27. The protein or protein fraction according to claim 26, wherein the culture is performed by continuous culture using hydrogen gas as an energy source and carbon dioxide gas as an inorganic carbon source.

28. The protein or protein fraction according to claim 26 or 27, wherein the isolation comprises mechanically disrupting cells and separating the protein from the cell fragments by one or more filtration or ethanol extraction steps.

29. A food or feed product comprising biomass, protein, or protein fraction according to any one of claims 17 to 28.

30. The food or feed product according to claim 29, provided as a processed food, food supplement, feed supplement, protein bar, protein powder, protein shake, meat substitute, food ingredient, probiotic product, prebiotic product, nutritional supplement, vegetarian food, or vegan food.

31. A method for producing a food or feed product, comprising incorporating the biomass, protein, or protein fraction described in any one of claims 17 to 28 into the food or feed product during its manufacture.

Images